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Abstract
Head and neck squamous cell carcinoma (HNSCC) is a challenging disease which 
causes significant morbidity and mortality. Tobacco and alcohol are the prime 
aetiological factors and incidence rates are much higher among people from deprived 
areas. Too many patients present with advanced disease. Unfortunately the substantial 
advances in established therapies, including surgery, radiotherapy and chemotherapy, 
have not had a significant impact on patient survival. Treatment failure is a 
significant problem and there is a great need for the development of novel therapies. 
Oncolytic viruses have been developed to selectively infect, replicate in and kill 
targeted cancer cells, while leaving healthy normal cells alone. HSV1716 is an 
avirulent HSV-1 mutant with a 759 bp deletion in both copies of the RLl gene 
(MacLean et al, 1991). HSV1716 has been characterised as a selectively replication 
competent vims and a potential novel cancer therapy. HSV1716 has not been 
previously investigated in HNSCC.
The aims of this thesis were to determine whether HSV1716 would replicate in and 
kill head and neck squamous cell lines, to determine if the cytotoxic effects in vitro 
were enhanced when combined with the conventional chemotherapeutic agent 
cisplatin and to carry out a phase I clinical safety trial involving the preoperative 
intratumoural injection of HSV1716 in patients with oral squamous cell carcinoma.
A panel of 3 HNSCC cell lines were used, and multicycle growth experiments were 
performed to investigate the permissivity to infection. HSV1716 was found to be able 
to replicate in the HNSCC cells and, during MTS assay studies, was found to be
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cytotoxic. However, the use of oncolytic viruses in isolation may not necessarily 
produce an efficacious effect comparable to, or better than currently available 
therapies. Combining agents with different mechanisms of cytotoxicity is an 
attractive approach and gives a number of potential advantages. It gives potential for 
using lower doses, maximising the therapeutic effect and minimising side effects. 
Combining therapies also gives potential for enlianced effects, tlrrough different 
mechanisms of cytotoxicity. These interactions can be additive or synergistic. 
Cytotoxicity studies were performed to evaluate the effect of combining HSV1716 
with the conventional chemotherapy agent cisplatin in 3 head and neck cell lines. 
Preliminary studies established there to be no toxic interactions between the two 
agents. Isobologram analyses following the cytotoxicity studies identified enlianced 
cell kill, with additivity, when HSV1716 was combined with cisplatin. We do not 
know the relationship between the mechanisms of action of these 2 agents and this 
needs further investigation.
For this therapy to be useful in head and neck cancer it was necessary to investigate j
: j
whether direct intratumoural injection of HSV1716 is tolerated well and is safe. We 3
conducted a Phase I study involving 20 patients with oral squamous cell carcinoma to .1
evaluate this. Patients received intratumoural injections of HSV1716, under local
.tanaesthetic, at intervals between 24 hours and 14 days preoperatively. Each patient 
also received an injection of HSV1716 into the contralateral normal buccal mucosa.
Doses ranged between 10  ^pfu 5x10^ pfu.
The therapy was found to be completely safe with no toxicity. The procedure was 
technically uncomplicated and well tolerated under local anaesthetic. HSV1716
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injection did not cause any clinically apparent tissue reaction. There were no signs of 
increased inflammation or ulceration of the injected tumour or buccal mucosa. H&E 
slides of sections of tissue at the tumour injection site did not identify any unexpected 
inflammation or necrosis. H&E slides of sections of tissue of injected normal buccal 
mucosa revealed lymphocyte infiltrations and no necrosis. Two out of 20 patients 
injected with HSV1716 were seronegative for HSV antibodies prior to injection. Both 
seroconverted within 5 weeks of their injection, indicating an immune response. HSV 
DNA was detected by PCR in injected normal mucosa in 3 patients up to 72 hours 
post-injection. There was no infectious virus recovered from any nonnal mucosa 
samples and no positivity in immunohistochemistry or in situ hybridisation analysis. 
Overall HSV1716 injection of normal mucosa appears to have consistently caused an 
inflammatory reaction, but no necrosis and we have found no evidence of viral 
replication.
Overall we have shown in vitro that the selectively replication competent oncolytic 
virus, HSV1716, is able to replicate in and kill HNSCC cell lines in vitro. 
Cytotoxicity studies have shown that there is additive enhanced cell kill when 
HSV1716 is combined with the conventional chemotherapy agent cisplatin. 
Following completion of a Phase I toxicity study we have shown that HSV1716 can 
be injected into patients with oral SCO readily, comfortably and safely. There was no 
toxicity in any of the 20 enrolled patients. The lack of toxicity is encouraging and 
suggests higher doses could be used in future trials. There was however little 
evidence of biological activity in the tumour specimens analysed in the clinical trial 
and further investigations are warranted into the reasons for this. As has been seen
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with other oncolytic viruses, the effective clinical application is not as straightforward 
as laboratory studies might have indicated. The principal problem areas involve 
optimising the delivery and distribution of HSV1716 into a dense heterogeneous SCC 
tumour cell matrix. Increasing our knowledge of the interactions between HSV1716, 
the HNSCC tumour cell and the immune system will help to optimise antitumour 
efficacy. This will maximise its ability to disseminate throughout a tumour mass and 
endure efficacy, despite encountering the immune response.
Current therapies for recurrent head and neck cancer, such as tumour debulking, 
further irradiation and chemotherapy have all produced poor responses of limited 
duration, and significant morbidity. HSV1716 has the potential to complement and 
improve conventional therapies.
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CHAPTER 1
INTRODUCTION
1. INTRODUCTION
1.1 SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Head and neck cancer is a clinically challenging disease. It encompasses a range 
of tumours, including squamous lesions of the upper aerodigestive tract, skin 
neoplasms and glandular neoplasms of the thyroid and major salivary glands. The 
majority o f cases involve squamous lesions o f the larynx and oral cavity. 
Squamous cell carcinoma (SCC) accounts for over 90% of oral malignancy, with 
the remainder including salivary gland neoplasms, sarcomas and lymphomas.
1.1.2 EPIDEMIOLOGY
More than 500,000 cases of head and neck squamous cell carcinoma (HNSCC) 
are diagnosed annually, and the UK incidence is over 10 per 100,000 population. 
Oral cancer accounts for 2-3% of all cancers in the UK, and currently there are 
over 300 new cases o f oral cancer diagnosed in Scotland each year (ISD Scotland, 
1999). It is an even bigger problem elsewhere in the world. In parts of India the 
incidence is 20 per 100,000 population, accounting for 40% of all malignancies. 
Oral SCC is predominantly a disease of the elderly with 72% occurring between 
55 and 75 years of age, and a mean age of 63 years (ISD Scotland, 1999). There is 
a higher incidence in males, although this ratio has decreased during the last 50 
years. Unfortunately there is an increased incidence among younger age groups, 
and the incidence is very much higher among people in deprived areas. (Scottish 
Cancer Intelligence Unit, 2000) (Figure I).
1.1.3 AETIOLOGY
Tobacco smoking (lARC, 2002) and alcohol consumption (lARC, 1988) are well 
documented as the most important aetiological factors in oral carcinoma.
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However variations in global incidences highlight cultural, environmental and 
genetic factors. Whereas smoking tobacco and drinking alcohol are significant in
D Survival Incidence - - A- - - Mortality
100
5 60
1 2 3 4 5
Least Most deprived
Deprivation quintile
Figure 1. ISD data: Oral Cancer. Incidence, mortality and cause specific 
survival at 5-years by deprivation. Patients diagnosed 1991-1995,
the West, chewing betel or areca nuts, smoking bidis and smoking snuff are 
particularly important in the Indian subcontinent (Moore et al, 2000). Cigarette 
smoke contains over 30 tumorigenic agents including benzanthracene and 
benzopyrene. Heavy smokers, smoking greater than 20 cigarettes per day, are 6 
times more likely to develop oral cancer than non-smokers. In patients who 
continue to smoke, there is a higher incidence o f second primary tumours (10- 
30% of patients) with a 2-3% risk each year (Silverman et al, 1983). Chewing 
tobacco and snuff dipping are potent causes of oral SCC in the area of the mouth 
where the tobacco is held. N-Nitrosamines are the most important carcinogenic 
agents in chewing tobacco. Alcohol itself is not carcinogenic but it may disturb
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the protective cellular lining of the oral cavity to allow access of co-carcinogens 
like tobacco. Evidence exists that there is a synergistic relationship in the effects 
of alcohol and tobacco (Saracci et al, 1987), although this is not always a 
consistent finding.
Unhealthy diets, vitamin deficiencies, particularly A, C and E, and poor dentition 
are recognised as risk factors for oral carcinoma. A study from Milan in North 
Italy found that o f 17 indicator foods, six were associated with a reduction in risk 
of oral and pharyngeal cancers (La Vecchia et al, 1991). These were milk, meat, 
cheese, carrots, green vegetables and fruit. This risk reduction persisted after 
adjustment for smoking and alcohol consumption.
Anaemia is also associated with oral carcinoma, and several studies have 
demonstrated the adverse impact of anaemia upon locoregional tumour control 
and suiwival (Overgaard et al, 1989; Fein et al, 1995; Warde et al, 1998). The 
mechanism of action of the anaemia is not fully understood.
The role of infectious agents as aetiological factors remains unclear. There has 
been some evidence implicating HSV-1 in the aetiology o f human oral 
carcinogenesis. Eglin et al, 1983 examined oral carcinoma specimens by in-situ 
hybridisation, for evidence of RNA complementary to HSV-1. A notable 66% of 
the carcinomas were positive. However the authors later discovered that the 
technique used deteeted areas o f homology between the HSV genome and human 
cellular DNA, transcribed to excess in proliferating cells. Nevertheless, Kumari et 
al, 1987 demonstrated HSV-1 antigens in 71% of biopsy samples from oral 
carcinoma. HPV type 16 DNA has been detected in oral carcinoma biopsies (de 
Villiers et al, 1985; Shroyer et al, 1991). However Young et al, 1991, did not 
detect HPV DNA in any biopsies of epithelial dysplasia or SCC. They confirmed
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the consistent and frequent finding of HPV in squamous cell papillomas, but the 
inconsistency o f identifying HPV DNA in oral keratotic, premalignant, or 
cancerous lesions. Overall the roles, if any, that HSV or HPV play in oral 
carcinogenesis remain unclear.
1.1.4 CLINICAL PRESENTATION
Most head and neck cancers present with symptoms from the primary site. For 
oral carcinomas this may be a persistent ulcer, with or without associated pain, a 
persistent red or white mucosal plaque, odynophagia or dysphagia. The patient 
may have no symptoms at all and the diagnosis made during a routine dental 
check-up or medical examination. It is not unconnnon to present only with an 
enlarged cervical lymph node, especially with certain “silent” sites such as the 
tongue base. Systemic métastasés are uncommon at presentation. Excluding SCC 
of the lower lip the most frequent sites for oral SCC are tongue, floor of mouth 
and mandibular alveolus. It is postulated that these areas form a “sump” into 
which carcinogen containing saliva pools, and can act over an extended period of 
time.
1.1.5 PREVENTION AND SCREENING
Primary prevention is crucial in tackling head and neck cancer, and is the most 
effective way to reduce mortality. Stopping smoking requires combating the 
chemical and psychological addiction, and ultimately requires personal 
motivation. Nicotine replacement therapy has been shown to be effective in 
approximately 13% of smokers who seek advice (Silagy et al, 1994). Early 
detection of premalignant or early stage disease is also paramount. One good 
thing about the presentation of oral carcinomas is that they are usually directly 
visible and accessible. However, this is very often not the case for base of tongue
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and more distal head and neck tumours. Increasing patient awareness of the 
symptoms attributable to oral cancer, and increasing primary care physicians’ and 
dentists’ knowledge of the symptoms, signs and indications for referral are 
fundamental. Unfortunately screening by dentists o f a self-selecting population 
does not target the high-risk heavy smokers and drinkers from deprived areas. 
Screening patients using a mouth rinse, containing Toluidine blue, has been tested 
with some effect to identify oral mucosal lesions (Wamakulasuriya et al, 1996). 
The big problem remains in trying to determine which lesions are likely to 
progress to malignancy. Epithelial dysplasia is the most important predictive 
faetor (Wamakulasuriya et al, 2000), but aberrant oncogenes (Werkmeister et al, 
1999), and integrin expression (Hamidi et al, 2000) may also be significant. 
Tobacco and alcohol are clearly defined as aetiological factors in HNSCC. 
However it remains unclear, for example, why only a fraction of smokers develop 
cancer. Genetic susceptibility may be significant and research is ongoing. 
Inheritable differences may exist in the efficiencies of the complex pathways of 
carcinogen metabolising systems, DNA repair systems, cell cycle controls or 
apoptosis pathways. Large family studies have demonstrated a three-to-eightfold 
increased risk of HNSCC in first-degree relatives of patients with HNSCC, 
indicating a genetic component. (Goldgar et al, 1994; Foulkes et al, 1995; Copper 
et al, 1995) Identifying high-risk individuals will be important in cancer 
prevention in the future.
There have been a number of trials using chemicals to suppress or reverse 
premalignant progression to invasive malignant disease. Agents used include 
retinoids (vitamin A, (3-carotene and 13 cis-retinoic acid), N-acetyl cysteine and 
seleniums. Chemoprevention using safe non-invasive drugs is appealing, but no
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evidence suggests these treatments are effective in routine clinical practice (Lodi 
et al, 2001).
1.1.6 REFERRAL AND DIAGNOSIS
In 1998 the Department of Health published a White Paper setting a target for all 
patients with suspected cancer to be seen by a specialist within 2 weeks of their 
general practitioner deciding that they need to be seen urgently (HMSG, 1998). 
Since then there have been an increasing number of one-stop clinics or quick and 
early diagnosis (QED) elinics for the management of head and neck lumps, 
dysphonia, dysphagia and lesions of the oral mucosa (Kendall et al, 1996). 
Unfortunately, at present, there is little public awareness o f head and neck cancer 
and too many people present with advanced disease.
All patients are referred to a multidisciplinary team, including a surgeon, clinical 
oncologist, nurse counsellor, dietician and speech therapist. Patients are often in 
poor general health, have comorbidities and psychosocial problems, and all team 
members are essential for a holistic approach to patient management. Ideally a 
specialist pathologist and radiologist should also be part of the team and, in 
particular for the management of oral carcinoma, a prosthetic technician is 
invaluable.
Once referred to a specialist centre, the diagnosis is confirmed by biopsy of the 
primary site and fine needle aspiration of any enlarged cervical lymph nodes. A 
panendoscopy is required to fully clinically stage the primary lesion and exclude 
any synchronous lesions in the upper aerodigestive tract. In the management of 
oral carcinoma an orthopantomogram is essential to assess dentition and to look 
for signs of bone invasion. Some centres also obtain a computed tomography scan 
from the base o f skull to the diaphragm, again to exclude synchronous lesions.
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The overall incidence of second primaries is 10-20%, (McGarry et al, 1992; 
Schwartz et al, 1994).
1.1.7 CLASSIFICATION AND STAGING
Accurate classification of head and neck cancer is crucial, both clinically and 
pathologically. The UICC TNM classification is used universally, and describes 
the anatomic extent o f the tumour (Table 1). In particular it relates to the primary 
site (T) and regional lymph nodes (N), and to whether métastasés exist beyond the 
regional lymph nodes (M). The TNM classification is a dual system with a clinical 
classification (cTNM), which is usually used pre-treatment, and a post surgical 
histopathological classification (pTNM). The former is used in making a decision 
on treatment, and the latter is used for the estimation of prognosis and the possible 
selection of adjuvant treatment.
Table 1 :
TNM CLASSIFICATION FOR ORAL SQUAMOUS CELL CARCINOMA
l u moil r 1
TIS Carcinoma in situ
T1 Tumour 2 cm or less in greatest dimension
T2 Tumour > 2 cm but no more than 4cm in greatest dimension
T3 Tumour > 4cm in greatest dimension
T4 Tumour with direct extension to bone, muscle, skin, neck
NO No evidence o f regional lymph node involvement
N1 Metastasis to ipsilateral lymph node no more than 3 cm diameter
N2a Metastasis to single ipsilateral lymph node >3em & <6cm diameter
N2b Métastasés in multiple ipsilateral lymph nodes, none >6cm diameter
N2c Métastasés in bilateral/contralateral lymph nodes, none >6cm diameter
N3 Métastasés in lymph nodes >6cm diameter
MO No evidence of distant métastasés
M l Distant métastasés present
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Staging into groups I-IV is done according to the TNM classification (Table 2). 
Table 2: ORAL CARCINOMA STAGES I-IV
Stauiiiii
Stage I T l NO MO
Stage II T2 NO MO
Stage III T3 NO, Tl-3 N1 and MO
Stage IV T4 any N, Tl-3 N2-3, any T and N M l
Unfortunately there is a significant amount of inaccurate TNM data recording. 
Accurate data recording and audit is crucial to evolve, compare and monitor the 
quality of cancer care. As a result the British Association of Head and Neck 
Oncologists have introduced National Minimum and Advisory Head and Neck 
Cancer data sheets. These will hopefully greatly improve the audit potential, 
especially when looking at the quality o f life and functional outcomes from 
treatment.
1.1.8 MANAGEMENT
Management o f head and neck cancer has to be considered in respeet to both the 
primary tumour and the cervical lymph nodes. Surgery and radiotherapy offer 
equally good long term results in small early tumours. When looking at either 
form of treatment, the associated early and late morbidity, quality of life and loss 
of function have to be considered. In general, function is better after radiotherapy 
than after surgery, but treatment time for surgery is shorter. Many early oral 
carcinomas are easily accessible for resection and especially if there is no neck 
disease, a relatively short anaesthetic is required. Radiotherapy usually involves 
attending daily, Monday to Friday, for 4-6 weeks.
More advanced oral carcinoma is usually managed by surgical resection, if 
possible, and postoperative radiotherapy. Chemotherapy is included depending on 
the presence of poor prognostic markers. These include close or involved excision
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margins, extranodal spread of tumour, multiple nodes and poorly differentiated 
pathology with perineural or perivascular spread.
A) Surgery
During the last 20-30 years there have been great advances in the surgical 
management of advanced disease. This has been aided by advances in anaesthesia 
to increase the safety of unhealthy patients undergoing long operations. Advances 
in the use of pedicled myocutaneous flaps and, more recently, with the use of free 
flaps, larger resection defects can be filled, while improving the patient’s loss of 
function and cosmetic disfigurement. Three common free flaps used in the 
management of oral carcinoma are the radial forearm free flap (Figure 2), 
anterolateral thigh flap and deep circumflex iliac artery flap (Figure 3).
Surgery is usually the first line of management of cervical node disease. The 
nodes are divided into five anatomical levels (Figure 4).
Figure 2: RADIAL FOREARM FREE FLAP
(Cutaneous flap: Left forearm flap is shown with the radial vessels dissected)
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Figure 3:DEEP CIRCUMFLEX ILIAC ARTERY FREE FLAP 
(Osseomyocutaneous flap: Skin paddle is shown overlying the left iliac crest)
Figure 4: Diagram of the neck showing lymph node levels I-V 
(Adapted from McMahon et al, 2000)
/
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Neck dissections are graded into radical, modified radical or selective surgery, 
depending on the levels o f nodes resected, and which “important” structures are 
resected en bloc.
Neck dissections
Radical Removes levels 1-5, stemomastoid muscle, internal jugular vein, 
accessory nerve
Modified Removes levels 1-5 but preserves:
Type 1—  Accessory nerve
Type 2—  Accessory nerve, internal jugular vein
Type 3— Accessory nerve, internal jugular vein, stemomastoid 
muscle
Selective Removal of only selected lymph node groups and preservation of 
other stmctures
Extended As classic procedure, but with the removal of additional lyuiph node 
groups or non-lymphatic stmctures such as overlying skin
In the clinical presence o f nodal disease, some type of modified radical dissection
is usually indicated. There has been a move away from performing radical
surgery. Modified radical dissection has been shown to be oncologically safe in
the N1 and N2 neck, while improving the significant morbidity, especially
shoulder disability, associated with radical surgery (Buckley et al, 2001).
Controversy remains over the potential indications for selective neck dissections.
If there is no clinical evidence of nodal disease, but the expected incidence of
node metastasis is greater than 20%, it is common practice to treat the neck (Table
3). The alternative is to wait and see. As yet there has not been a prospective
randomised trial comparing the 2 approaches.
Unfortunately the advances in surgery have not been paralleled with increased 
patient survival. Research continues into the best regimens and indications for 
radiotherapy and chemotherapy, while constantly exploring novel therapies.
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Oral tongue 22 62
Floor of mouth 20 49
Tonsil fossae 71 80
Base of tongue 69 79
Nasopharynx 88 86
Supraglottis 41 62
Pyriform sinus 34 77
Glottis 5 20
Table 3: Incidence of nodal métastasés by site and T stage of primary tumour
(Lindberg, 1972)
B) RADIOTHERAPY
Radiotherapy has been used to treat head and neck cancer for decades, and it 
remains unclear what the optimum regimens are for patient groups. Trial data is 
confused by the inclusion of patients with varying subsites of disease. New 
regimens are compared to conventional therapy, which in itself has varying 
schedules throughout the UK and the rest of the world. Current regimens are not 
always based on scientific evidence, but on resource limitations. Demands on staff 
and machinery are usually the reason for delays in oncological therapies.
A typical regimen for conventional radiotherapy in the UK would involve a total 
dose of 66 Gray (Gy), given in 33 doses or fractions. Important factors in the 
efficacy o f radiotherapy are the total dose, the number o f fractions, the resulting 
dose per fraction and the overall treatment time. As with chemotherapy the 
therapeutic ratio between the effects on the tumour and on normal tissue in the 
radiation field are crucial. Strategies to improve the outcomes from radiotherapy 
have concentrated on altering radiation fraction schedules. Hyperfractionation
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involves giving multiple smaller fractions, with an aim of decreasing the 
incidence of late radiation changes (Fowler, 1984). A higher overall dose can 
therefore be given without incurring excessive late damage, with the objective of 
improving tumour control. Late tissue damage can occur months to years after 
irradiation. The EORTC 2791 trial compared a hyperffactionated schedule of 80.5 
GY given in 70 fractions twice per day, over 7 weeks, with a conventional dose of 
70 Gy using 35-40 daily fractions (Horiot et al, 1992). Five-year local control was 
increased from 40% in the daily fractionation, to 59% in the hyperfractionated 
arm. The improvement in locoregional control was not associated with an increase 
in late tissue damage.
Accelerated fractionation involves reducing the overall treatment time while 
maintaining the same or a similar number o f fractions as for conventional 
radiotherapy. This is thought to allow less time for tumour cell division during 
treatment, and accelerated repopulation due to exposure to radiation. This 
approach is associated with increased mucosal toxicity and dose reduction is 
necessary (Skladowski et al, 2000).
Accelerated Hyperfractionation aims to achieve both objectives of increasing 
locoregional control and decreasing late tissue damage, Saunders et al, 1991, 
compared continuous, hyperffactionated, accelerated radiotherapy (CHART) with 
conventional therapy in patients with head and neck and bronchial carcinoma. 
Locoregional control in the head and neck patients was 90% in the CHART group 
compared to 62% in the conventional treatment arm. Increased acute mucositis 
was significant in the CHART group, but late changes in the skin, mucosa, 
connective tissues and salivary glands were reduced. Bigger randomised 
multicentre trials followed. The EORTC 22851 trial conob orated the finding of
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increased locoregional control with 13% increase after 5 years in the accelerated 
hyperffactionated group (Horiot et al, 1997). In this study patients in the 
experimental arm were given a rest period of 12-14 days in the middle of a 5 week 
regimen to allow recovery o f the normal epithelium. However the increased acute 
and late morbidity was significant. Severe late toxicity occurred in 14% of 
patients in the accelerated ffactionated group, including 2 cases of radiation 
induced myelitis. Dische et al, 1997 conducted a larger CHART trial involving 
918 patients randomised between conventional therapy and an accelerated and 
hyperfractionated schedule of 54 Gy in 36 fractions over 12 days. There was no 
difference in locoregional control between the 2 arms, but reduced late morbidity 
in the CHART arm.
A more novel approach to radiotherapy involves intensity modulation. This aims 
to give an even distribution of radiation dose within a target tumour, which is 
naturally irregularly shaped. It aims to spare the surrounding normal tissue and so 
allows for escalation of the radiation dose (Nutting et al, 2000). The technique is 
complicated, time consuming and clinical trials are required to prove its benefit. 
Overall, the evidence for the optimal external radiotherapy regimen remains 
inconclusive. There are too many variables between fractionation parameters, 
head and neck cancer subsites included in trials, the staging of the carcinomas 
included and tangibly significant molecular biological differences in the 
carcinomas. It remains unclear why a percentage o f head and neck carcinomas at a 
particular subsite respond to radiotherapy and others do not. Unfortunately this 
means that some patients are enduring treatment side effects with no chance of 
benefit.
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Brachytherapy is the implantation of radioactive sources directly into the tumour. 
High doses of radiation are delivered to the tumour while sparing healthy 
surrounding tissues. This teclinique can be used for the primary treatment of 
tumours, or for boosting to the primary tumour after locoregional external beam 
radiotherapy. In the latter, it is important that the external treatment and 
brachytherapy run close together to avoid any extension in the overall treatment 
time. It can also be used as salvage therapy in previously iiTadiated tumours where 
no further external radiotherapy can be given. There are a number of potential 
benefits for its use in head and neck cancer. Notably structure and function is 
preserved, and this is particularly relevant to tongue carcinomas where the 
destruction and disability from a glossectomy are considerable. Also avoiding or 
reducing external beam radiotherapy means nearby critical structures, including 
brain, eyes and spinal cord, are spared. Wound infection, breakdown and pain are 
the most common complications of this therapy.
C) CHEMOTHERAPY
Chemotherapy in the past has been reserved for palliative therapy for head and 
neck cancer patients. It is now a cormnon component in the curative management 
of advanced (stage III and IV) HNSCC. The most commonly used combination 
agents are platinum-based cisplatin and 5-fuorouracil (5-FU). This combination 
has been shown to have significantly higher response rates than single agents 
alone, although there is no survival benefit and toxicity is increased (Forastiere et 
al, 1992; Jacobs et al, 1992), Newer drugs have been investigated to try and 
improve patient survival. Taxanes, including docetaxel and paclitaxel, have 
significant activity in head and neck cancer. Early trial response rates were high, 
at up to 40%, but acute toxicity was high too. Severe or life-threatening
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granulocytopenia affected 91% of patients in one trial (Forastiere et al, 1998). 
New combination regimens pairing standard agents, such as cisplatin, with new- 
generation drugs have shown some promising results. But they have not shown 
superiority over cisplatin and 5FU. Toxic effects, including myelosuppression, 
have been significant.
For patients presenting with locally advanced HNSCC, standard treatment 
includes radical surgery and/or radiotherapy. Unfortunately the long-term survival 
of these patients remains poor. To try and improve the prognosis in these patients, 
chemotherapy has been investigated as a treatment in head and neck cancer for 
decades. Different approaches have been investigated, including administering the 
chemotherapy before definitive surgery and/or radiotherapy (neoadjuvant), during 
radiotherapy (concomitant), or following completion of surgery and/or 
radiotherapy (adjuvant).
Neoadjuvant therapy was investigated for many years. The main aims were to 
potentially allow for greater organ preservation, improve local and distant disease 
control, and improve survival. Many randomised trials were conducted, but most 
were too small to detect even a moderate effect on survival. The Meta-Analysis of 
Chemotherapy on Head and Neck Cancer (MACH-NC) analysed 63 trials of 
locoregional treatment with or without chemotherapy. They concluded there is no 
survival benefit associated with neoadjuvant therapy (Pignon et al, 2000). Other 
meta-analyses have drawn the same conclusions (El-Sayed et al, 1996; Browman, 
1994). Neoadjuvant chemotherapy used with an aim o f organ preservation 
remains investigational (The Department o f Veteran Affairs Laryngeal Cancer 
Group, 1991; Lefebvre, 1996). Trials have compared radical surgery and 
radiotherapy with neoadjuvant chemotherapy and radiotherapy in responders; or
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neoadjuvant chemotherapy, radiotherapy and salvage surgery in non-responders. 
Patterns o f recurrence differed between the groups, with more local recurrences 
and less distant métastasés in the chemotherapy group than in the surgery group. 
Jacobs et al, 1987, treated 30 patients with resectable stage III or IV, MO head and 
neck cancers in the oral cavity, oropharynx, hypopharynx and larynx with three 
cycles of neoadjuvant cisplatin and 5FU. 40% of patients responded completely 
and were treated with radiotherapy alone, sparing surgery. The partial or non­
responders underwent salvage surgery and postoperative radiotherapy. There was 
no significant difference in the relapse-free survival at 2 years. This indicates that 
patients with complete pathological responses to neoadjuvant chemotherapy could 
be spared surgery, with no compromise to their survival. A significant problem is 
not being able to predict a tumour’s response.
Analyses of adjuvant therapy trials have not shown any survival benefit (Munro, 
1995; Pignon et al, 2000). However the use of concomitant chemotherapy and 
radiotherapy offers the most promising data. Pignon et al, 2000, in their meta­
analysis showed an absolute survival benefit of 8% at 2 and 5 years with 
concomitant therapy. Unfortunately this result came from a number of very 
heterogeneous trials involving only 11% of the patients analysed, and so needs 
corroboration. Browman et al, 2001, analysed 18 randomised controlled trials 
involving concomitant therapy, and showed a survival benefit of 11%, but with 
significant acute toxicity. Platinum-based regimens were used in nearly half of the 
patients, and were the most effective. Acute toxicity is increased by most 
regimens of simultaneous chemoradiotherapy, and the late tissue effects may be 
enhanced. This implies that regimens are not necessarily improving the 
therapeutic ratio.
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1.1.9 PROGNOSIS
Overall the modifications of established cancer therapies, including surgery, 
radiotherapy and chemotherapy, have not had a significant impact on patient 
survival. Most patients with HNSCC present with advanced disease, with 
incidences of locoregional recurrence and distant métastasés at 50% and 25% 
respectively. Five-year survival rates for stage III and IV disease range from 0% 
to 40%, depending on site and resectability status (Forastiere, 1994). 
Unfortunately the patient with recurrent or metastatic disease is often considered 
incurable. Treatment failure is a significant problem and there is a great need for 
the development of novel therapies.
1.2 MOLECULAR GENETICS OF HEAD AND NECK CANCER
The process o f carcinogenesis is complex and involves many genetic mutations. 
At least 10 independent genetic alterations are required to convert a normal cell 
into a squamous carcinoma cell (Renan, 1993). During this transition the normal 
regulation of the cell cycle is lost. An important aim for investigating head and 
neck cancer genetics is to find markers to indicate the most effective type of 
treatment or prognostic indicators of patient survival. Understanding of the 
molecular genetics may also permit the development of new cancer therapies.
1.2.1 CYTOGENETICS
Cytogenetic characterisation of HNSCC identifies multiple complex chromosomal 
breakpoints, gains and losses. The most frequent changes usually involve 
deletions, with losses commonly affecting chromosomes 3p, 5q, 8p, 9p, and 18q 
(Van Dyke et al, 1994). Loss of 18q is associated with a poor prognosis and losses 
of 3p21 and 8 p ll are associated with radioresistance. Breakpoints in I lq l 3  have 
been associated with radiosensitivity (Cowan et al, 1993). These markers could be
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useful in predicting a tumour’s response to radiotherapy. Califano et al, 1996, 
proposed a model for head and neck carcinogenesis (Figure 5).
The normal cell cycle is controlled in 2 main ways: a cascade of protein (CDK- 
cyclin complexes) phosphorylations that relay a cell from one stage to the next, 
and a set o f checkpoints that monitor completion of critical events (Figure 6). 
Figure 5: HUMAN CELL CYCLE
1.2.2 ONCOGENES
Naturally occurring proto-oncogenes encode proteins that regulate normal cell 
proliferation or apoptosis. If mutations occur they become oncogenes with 
resulting increased function or over-expression and unregulated cellular 
proliferation. Examples include cyclin D l, erbB, ras, and SCCRO. The proto­
oncogene Cyclin D l is a cell cycle regulator localised to chromosome l l q l3 ,  and 
is commonly amplified in HNSCC. This amplification has been correlated with a 
poor prognosis (Callender et al, 1994; Namazie et al, 2002). Over-expression is 
also associated with occult cervical métastasés, early recurrence and shortened 
survival (Michalides et al, 1995; Capaccio et al, 2000).
Ras genes, including H-ras, K-ras and N-ras, are rarely mutated in HNSCC at a 
frequency of <5% in the Western world (Yarbrough et al, 1994; Matsuda et al, 
1996). However some studies have indicated over-expression is involved in oral 
carcinoma (McDonald et al, 1994). Interestingly Hoa et al, 2002, found the level 
o f K-ras protein expression to be a major detenninant of HNSCC proliferation and 
the amplification of K-ras to contribute to tumour growth.
Epidermal growth factor receptor (EGFR), erb-Bl, is part o f the erb-B family of 
receptor tyrosine kinases.
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(The cell cycle consists of four ordered phases Gap 1 (Gl), DNA synthesis (S), 
Gap 2 (G2) and DNA mitosis (M). Stimulatory (+) and inhibitory (-) proteins 
control the cycle. Genetic mutations in cancer cells cause defects in the cell 
cycle regulation.)
EGFR expression is reported in up to 90% of HNSCC, and is associated with a 
poor prognosis (Grandis et al, 1996; Ke et al, 1998). It has a complex role and 
signal transduction pathways contribute to the development of malignancies 
through various processes, including cell cycle progression, inhibition of 
apoptosis, angiogenesis and métastasés.
Squamous cell carcinoma-related oncogene (SCCRO) is located on chromosome 
3q. It is overexpressed in oral carcinoma, and this expression has been correlated
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with aggressive clinical behaviour, including nodal métastasés and poorer survival 
outcome (Estilo et al, 2003).
1.2.3 TUMOUR SUPPRESSOR GENES
Tumour suppressor genes encode either negative regulators o f the cell cycle or 
positive regulators of apoptosis. Many are involved in DNA repair and mutations 
lead to loss of function and prevent maintenance of genomic stability. Examples 
include p53, Retinoblastoma (Rb), p l6  and p21.
p53 is a tumour suppressor gene located on the short arm (p) of chromosome 17. 
Once activated the p53 protein can induce growth arrest as well as cell death 
(apoptosis). Mutations in the p53 gene are found in up to 40-50% on HNSCC 
(Greenblatt et al, 1994). Alcohol and tobacco are associated with these mutations, 
but there does not appear to be a clear correlation between mutation and poor 
prognosis (Boyle et al, 1993; Brennan et al, 1995). In tumour cells the 
enhancement of p53 expression has been demonstrated after exposure to 
anticancer agents, which suggests its role in triggering cellular responses to these 
drugs (Eastman, 1990). Further, loss of p53 function has been linked to resistance 
to chemotherapy, and mutant p53 could prevent cells from undergoing apoptosis 
induced by cytotoxic agents (Lowe et al, 1993, Lowe et al, 1994).
Retinoblastoma is an important tumour suppressor gene involved in controlling 
the cell cycle. Study results looking at the incidence of Rb abnonnalities in 
HNSCC vary significantly, between 6% and 74%, and there does not appear to be 
a clear correlation between Rb mutation and poor prognosis (El-Nagger et al, 
1999; Koontongkaew et al, 2000).
p i6, p21 and p27 tumour suppressor genes act to modulate cell proliferation. 
Abnormalities of p l6  are common in HNSCC, with low expression in most head
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and neck cancers. Abnormal p l6  is associated with decreased survival, increased 
recurrences, tumour progression and nodal métastasés (Jares et al, 1997; Danahey 
et al, 1999; Bova et al, 1999). Expression of p21 and p27 is variable in HNSCC, 
and there is no clear relationship between p21 staining and clinical outcome. The 
presence of p27 has been correlated with improved survival (Pruneri et al, 1999; 
Tamura et al, 2001).
1.2.4 TELOMERASE
Telomeres are tandem repeats o f DNA associated with specific proteins, and 
function to cap the ends of chromosomes and maintain their integrity. In doing so 
they prevent chromosomes from fusing together and stops their ends being 
processed in the same way as broken DNA ends. Telomerase is a cellular 
ribonucleoprotein reverse transcriptase responsible for replenishing the telomeric 
DNA, as telomeres shorten with each cell division. Telomerase activity is 
completely repressed in most somatic cells, and so telomere length is not 
adequately maintained throughout life. Cell mortality ensues this replicative 
senescence. Telomerase activation is an important event in the conversion of a 
normal cell to a malignant cell. This results in an immortal phenotype with loss of 
replicative senescence. This state can arise early in HNSCC progression, but 
generally is more common in advanced disease (McGregor et al, 1997; Edington 
et al, 1995). Mao et al, 1996, showed telomerase expression in 90% of primary 
HNSCC and 100% of pre-malignant lesions.
1.3 GENE THERAPY IN HEAD AND NECK CANCER
There are several approaches being investigated in the development of novel 
therapies for head and neck cancer including gene therapy, antibody therapy and 
viral oncolytic therapy.
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1.3.1 PRINCIPLES OF GENE THERAPY
The aim of cancer gene therapy is to introduce new genetic material into target 
cells, for a therapeutic effect, without toxicity to non-target tissues. This includes 
the transfer of new genetic material as well as the manipulation of existing genetic 
material. Two key factors in its success are the mode of delivery and the 
transfection efficiency.
Transfer of genes may either be in vivo, in which the DNA and vector are directly 
introduced into the body, or ex vivo, in which cells are removed from the body, 
transfected with DNA and then reintroduced into the patient. The accessibility of 
oral cancer lesions readily allows the direct, in vivo, injection of genetic material. 
Gene therapy has the potential to treat primary, recurrent or inoperable disease, by 
injecting surgically resected margins or injecting the tumour directly. Systemic 
therapy is most desirable to target metastatic disease, although it presents 
significant problems.
Our increasing knowledge of cancer molecular genetics gives direction to the 
different strategies utilised in gene therapy. These include adding a tumour 
suppressor gene (gene addition therapy); deletion o f a defective gene (gene 
excision therapy); down-regulation of the expression of genes that stimulate 
tumour growth (antisense RNA); enhancement of immune surveillance 
(immunotherapy); activation of prodrugs that have a chemotherapeutic effect 
(“suicide” gene therapy or gene directed enzyme pro-drug therapy, GDEPT); 
introduction of viruses that destroy tumour cells as part of the virus replication 
cycle; delivery of a drug resistance gene to normal tissue for protection from 
chemotherapy and the introduction of genes to inhibit tumour angiogenesis.
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1,3.2 GENE DELIVERY VECTORS
A) CHEMICAL AND PHYSICAL VECTORS
The therapeutic gene is transferred into the tumour cells using chemical, physical 
or viral vectors. Chemical transfection introduces DNA by calcium phosphate, 
lipid or DNA/protein complexes. Lipid vectors are generated by a combination of 
plasmid DNA and a lipid solution that result in the fonnation of a liposome. 
Liposomes, as with protein complexes, are rapidly cleared from the body via the 
immune system, thus this mode has limited use clinically due to transfection 
inefficiency. Physical methods o f DNA transfection include electroporation, 
microinjection and the use of ballistic particles. During electroporation high- 
voltage electric impulses can be delivered into a tumour, cell membrane 
permeability is increased with enhanced uptake of naked DNA, for example, after 
injection, Allegretti et al, 2001, demonstrated that electroporation was safe and 
effective in 14 patients with squamous cell carcinoma. Particle bombardment has 
been studied to deliver genes to the oral mucosa in pre-clinical models, although it 
is limited by transfection inefficiency (Shillitoe et al, 1998). Overall nonviral 
vectors have advantages in terms of simplicity of use, ease of large-scale 
production and lack of specific immune responses, however transfection 
efficiency is a problem.
B) VIRAL VECTORS
Viral vectors commonly used in cancer gene therapy are retroviruses (including 
lentiviruses), adenoviruses and herpesviruses. Viruses are obligate intra-cellular 
parasites and tend to be very efficient at transfecting their own DNA into host 
cells. This DNA is expressed to form new viral particles. The aim in developing a
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viral vector is to eliminate the pathogenicity of a specific virus, while retaining the 
efficiency o f gene transfer and expression,
i) RETROVIRAL VECTORS
Retroviruses are RNA viruses that undergo reverse transcription after infecting a 
dividing cell, thereby producing double-stranded DNA. This DNA integrates 
stably into the host genome, thus passing copies of the genes to all specific 
generations of cells. Transfection is efficient and gene expression is pennanent, 
which is advantageous in situations where long-term expression of the transgene 
is required. This is pertinent to inherited conditions such as cystic fibrosis, 
however permanent expression raises long-term safety concerns. Another concern
is the random DNA integration, which may be harmful if  germ cell transfection in
occurs. The use of retroviruses is limited in solid tumours due to the low 
production titre that can be produced, thus reduced transduction efficiency,
ii) ADENOVIRAL VECTORS
Adenoviruses are double-stranded DNA viruses that infect a cell, lose their 
protein coat, and transfer DNA into the nucleus, where it is transcribed. This DNA 
does not integrate into the host genome, and so its effects are transient. To 
generate a defective adenovirus for gene transfer application, certain genes 
involved in viral gene expression and replication can be removed. The transgene 
can then be introduced into the vacated site. Adenoviruses have a larger genome 
than retroviruses, allowing more regions of DNA to be removed with transgenes 
of up to 36 kb inserted. The advantage o f adenoviral vectors is that most cells are 
susceptible to infection, regardless of their position in the cell cycle. Also 
transduction efficiency is enhanced due to the production of relatively higher 
titres. Since exposure to adenovirus in the community is common, approximately
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90% of humans have already formed antibodies against the virus. Pre-existing 
antibodies can limit the effectiveness, particularly on second exposure to the 
vector (Mack et al, 1997). Another disadvantage of adenoviral vectors is that they 
continue to express other viral products, which are recognised by the immune 
system. This can lead to an inflammatory response and short-term gene 
expression.
iii) HERPES SIMPLEX VIRAL VECTORS
Most herpes simplex virus vectors are developed from strains of herpes simplex 
virus type 1 (see section 1,6). The double-stranded DNA virus infects cells, 
replicates within the cells and causes cell lysis thereby infecting surrounding cells. 
Genes can be transferred rapidly and efficiently. HSV has several proteins that are 
expressed early in infection, and these in turn activate expression from the other 
HSV promoters. Inactivation of one or more of these immediate early proteins, 
ICPO, ICP4, ICP22, ICP27 and ICP47 results in a replication defective vector, 
except in a complementing cell line (Marconi et al, 1996; Wu et al, 1996; Zhu et 
al, 1996).
HSV vectors have the advantages of being able to infect non-dividing cells and 
establish latency in some cell types. Also many HSV proteins are nonessential for 
viral replication and can therefore be deleted to permit the insertion of large 
exogenous coding regions into the viral genome.
1.3.3 GENE THERAPY STRATEGIES IN HEAD AND NECK CANCER
A) P53
There have been a variety of gene therapy strategies for oral carcinoma. The most 
extensively studied mutations in oral cancer are those of p53. p53 plays a role in 
cell cycle regulation and in apoptosis. In vitro and in vivo studies using p53 gene
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transfer into HNSCC, via a replication deficient adenoviral vector, showed 
suppression of tumour growth by apoptosis (Liu et al, 1994; Liu et al, 1995). The 
over-expression of the transferred wild type p53 becomes dominant over its 
mutant gene, resulting in programmed cell death, daym an et al, 1998, conducted 
a clinical trial using adenoviral-p53 in patients with advanced HNSCC. Results 
showed this approach to be safe, well tolerated and some signs of activity were 
observed. However the viral transduction appeared to be low. A further in vitro 
study showed that the retinoid, All-trans-retinoic acid, given 72 hours pre-viral 
therapy, enhanced the adenoviral-p53 expression and synergistically induced 
apoptosis in HNSCC (Nakashima et al, 2001).
B) EPIDERMAL GROWTH FACTOR RECEPTOR 
RNA that is complimentary to a strand of DNA expressing a gene can inhibit gene 
expression. This “antisense” RNA can prevent the activity of oncogenes, 
including EGFR and its ligand, transforming growth factor alpha (TGF-a). Pre- 
clinical studies using a liposome mediated gene transfer of plasmids capable of 
expressing antisense EGFR or TGF-a in HNSCC, have shown tumour growth 
inhibition, suppression of protein expression and increased apoptosis (He et al, 
1998; Endo et al, 2000). A Phase I study is under way to determine the safety of 
liposome-mediated intratumoural EGFR antisense gene therapy, at the University 
o f Pittsburgh, USA. The successes of this approach depend on introducing 
sufficient quantities o f antisense molecules to dowmegulate the target gene, and 
inhibit tumour growth. A potentially more efficient method involves using small 
interfering RNAs (siRNA), which mediate mRNA degradation in the process of 
RNA interference (RNAi) (Bertrand et al, 2002). RNAi is the degradation of
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cellular RNAs by gene specific double stranded RNA. The increased efficiency is 
due to enlianced resistance of siRNAs to nuclease degradation.
C) IMMUNOTHERAPY
Immunotherapy is used to enhance the patient’s immune response to a tumour or 
enhance the immunogenic potential of tumour cells. Unsuccessful attempts have 
been made to enhance the patient’s immune response with the non-specific 
immunostimulant Bacillus Calmette-Guerin (Papac et al, 1978; Taylor et al, 
1983)). However OK-432, a non-specific cytokine inducer prepared from human 
streptococcus pyogenes, has been shovm to cause tumour regression (Kitahara et 
al, 1996).
Pre-clinical studies have been successful in enhancing the immunogenic potential 
of tumours, by transfecting tumours with cytokines such as the interleukins IL-2, 
IL-4 and IL-12; tumour necrosis factor-alpha (TNF-a) or the growth factor 
granulocyte macrophage colony-stimulating factor (GM-CSF) (Boscia et al ,1988; 
Wliiteside et al, 1996, Sacchi et al, 1990). The use of combined IL-2 and IL-12 
non-viral gene therapy in a HNSCC murine model resulted in significant anti­
tumour effects, most likely due to increased activation of cytolytic T-lymphocyte 
and natural killer cells (Li et al, 2001).
Tumour cells frequently have low levels of class I major histocompatibility 
complex (MHC) proteins, which limits the ability o f these cells to present 
antigens to cytotoxic T cells. Lang et al, 1999, have shown that there is 
impairment of T cell activation in head and neck cancer patients and this is partly 
due to B7 expression. If tumour cells are transduced with low levels of class I 
MHC alloantigens they become less oncogenic (Tanaka et al, 1985; Wallich et al, 
1985; Plautz et al„ 1993). These pre-clinical findings led to the development of
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Allovectin-7 and a phase I clinical trial (Gleich et al, 1998). Allovectin-7 is a drug 
designed to produce expression of HLA-B7, a class I MHC protein, in patients 
with head and neck cancer. It contains a cationic lipid complexed to a respiratory 
syncitial virus promoter and plasmid DNA that encodes the HLA-B7 heavy chain. 
Patients with advanced HNSCC received intratumoural injections of Allovectin-7, 
with no toxic effects and tumour regression in 4 out of 9 patients. Similar results 
were found in a larger multi-centre trial, and an efficacy trial is under way (Gleich 
et al, 2001).
D) GENE-DIRECTED ENZYME PRODRUG THERAPY
Gene-directed enzyme prodrug therapy (GDEPT), also known as “suicide “gene 
therapy, is a technique that involves physical delivery into a cell of a gene whose 
protein product enables a non-toxic prodrug to be activated into an active 
cytotoxic drug. This process relies on a bystander effect, as expression of the 
foreign enzymes does not occur in all cells of a targeted tumour. There are 
different theories explaining the cytotoxicity in untransfected cells including gap 
junctional communication, local inflammation, haemorrhagic necrosis and the 
production of Fas and FasL, both members of the tumour necrosis factor family 
(Elshami et al, 1996; Floeth et al, 2001; Hall et al, 2002). The success of this 
approach depends on the design of the gene therapy vectors, the chemistry of the 
pro drugs and their toxic metabolites and the means of delivery specifically to 
target cells. This is in addition to the efficiency of the bystander effect. The 
enzymes used fall into two categories. The first comprises foreign enzymes of 
non-mammalian origin, with or without human homologues. Examples include 
viral thymidine kinase (TK), bacterial cytosine deaminase (CD), carboxypeptidase 
G2 (CPG2), purine nuceoside phosphorylase (PNP), and nitroreductase (NR). The
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second category comprises enzymes of human origin that are absent or are 
expressed only at low concentrations in tumour cells. Examples include 
deoxycytidine kinase (dCK) and cytochrome P450. Enzymes from the first group 
have the potential of eliciting an immune response, unlike dCK or cytochrome 
P450. However use o f the second group may result in some prodmg activation in 
normal cells. A common example of GDEPT is the combination of HSV- 
thymidine kinase (HSV-TK) and the nucleoside analogue ganciclovir. Ganciclovir 
is an antiviral drug that is phosphorylated by HSV-TK and then by cellular 
kinases to produce ganciclovir triphosphate, which disrupts DNA syntheses during 
S phase resulting in cell death (Matthews et al, 1988). This approach selectively 
targets actively dividing cancer cells. The vectors used can be chemical, physical 
or viral, but there has been relatively little research using GDEPT in HNSCC. An 
in vivo study using adenovirus mediated gene transfer of the HSV-TK gene did 
show tumour regression in a murine SCC model (O’Malley et al, 1995; Sewell et 
al, 1997).
1.4 OTHER NOVEL BIOLOGICAL AND CHEMICAL THERAPIES
Other novel therapies include anti-EGFR monoclonal antibodies, EGFR tyrosine 
kinase inlnbitors and farnesyl kinase inhibitors to target ras genes. Cetuximab 
(IMC-C225) is an anti-EGFR monoclonal antibody that has been shown to be safe 
in phase I clinical trials (Baselga et al, 2000; Shin et al, 2001). A xenograft model 
has shown cetuximab to enhance the antitumour efficacy of chemotherapy agents 
such as cisplatin and doxorubicin (Shin et al, 2001, Baselga et al, 1993). A phase 
II trial showed cetuximab to be well tolerated when combined with platinum 
based chemotherapy in patients with recurrent or metastatic HNSCC. The tumour 
response rate was 10% (Baselga et al, 2005)
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ZD 1839 is a selective EGFR tyrosine kinase inhibitor. Pre-clinical studies have 
shown it to inhibit cellular proliferation in SCC cell lines, and enhance cisplatin- 
induced apoptosis and radiosensitivity in oral SCC cell lines (Magne et al, 2002). 
A phase I trial showed ZD 183 9 to be well tolerated with some antitumour activity 
observed (Baselga et al, 2002).
Farnesyl transferase inhibitors (FTIs) are a class of compounds that inhibit a 
critical step in the expression of mutated ras genes (Sepp-Lorenzino et al, 1995). 
Several novel FTIs have been developed including R 115777, SCH66336 and L- 
778,123. Pre-clinical studies have shown that these agents have potential activity 
in various solid tumours, including HNSCC (Chun et al, 2003). The exact 
mechanism of action appears unclear, as in vivo studies have shown antitumour 
activity in the absence of ras mutations (Sepp-lorenzino et al, 1995; End et al, 
2001). Famesylated proteins other than ras may contribute to the action of FTIs. A 
toxicity study demonstrated the FTI, L-778,123, to be well tolerated when 
combined with HNSCC. Some anti-tumour response was observed without an 
increase in radiotherapy toxicity (Hahn et al, 2002).
1.5 ONCOLYTIC VIRUSES
1.5.1 PRINCIPLES OF ONCOLYTIC VIRAL THERAPY
For several decades viruses have been investigated as a means of killing tumour
cells (Wheelock et al, 1964; Asada, 1974). Smith et al, 1956, described the use of
adenoviruses in the treatment of cancer where tumour necrosis was shown 
following direct intratumoural injection in patients with cervical cancer. Our 
greater understanding of molecular genetics during the last 15 years has enabled 
the design of far more effective oncolytic viruses. Martuza et al, 1991, first
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demonstrated the potential utility o f genetically engineered replication-selective 
viruses for cancer treatment, treating gliomas in nude mice.
The perfect oncolytic virus is one that selectively infects, replicates and kills 
targeted cancer cells, while leaving healthy normal cells alone. During this 
process the virus replicates to levels that are many logs higher than the input dose. 
Research has concentrated on a number of different oncolytic viruses, particularly 
adenovirus and HSV in head and neck cancer. Some are naturally attenuated viral 
strains, including some strains o f reovirus or vesicular stomatitis virus that infect 
or replicate more effectively in cancer cells. Adeno-associated virus has been 
shown to selectively induce apoptosis in cells that lack active p53 (Raj et al, 
2001). Other viruses, such as HSV-1 and adenovirus, are genetically modified to 
produce oncolytic effects. A significant disadvantage o f current gene therapy 
vectors is the poor tumour transduction, despite any bystander effects. Using a 
replication competent vims that selectively replicates in tumour cells overcomes 
this problem.
The selectivity for cancer cells can occur either during infection or during 
replication. Vims es can be engineered, for example, by altering their surface 
proteins to recognise cellular receptors specific to tumours. Alternatively the viral 
genes required for efficient replication can be modified, so that the virus only 
replicates in cells that have dismptions in normal homeostatic pathways. This 
could involve tumour suppressor gene defects or oncogenic pathways.
1.5.2 ONCOLYTIC ADENOVIRUS
A common genetic defect in HNSCC involves the p53 tumour-suppressor 
pathway, which can be targeted using adenovims. Cellular DNA damage results
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in p53 induced cell-growth arrest or apoptosis. This same cellular stress response 
results from viral infection, which eliminates propagation of the virus. The 
ElB55kD adenoviral protein has been thought to block p53 activity, prevent 
apoptosis and allow adenoviral replication. Adenovirus lacking ElB55kD, ri/1520 
(ONYX-015), was successfully engineered to selectively replicate in and lyse 
cancer cells that have defects in p53 function (Bischoff et al, 1996). The exact 
mechanism of action remains unclear, as altering a viral gene can affect several 
cell functions. Deleting ElB55kD provides the virus with some tumour 
specificity, but it also affects other phases of the viral cycle that reduce the 
efficacy of viral replication and oncolytic activity (Harada et al, 1999). 
Consequently several viral gene products might have to be altered to improve 
replicative selectivity.
ONYX-015 was the first genetically engineered, replication-selective virus to be 
used in huimans. Safety was of paramount concern and a staged clinical research 
and development approach was designed to increase systemic exposure to the 
virus sequentially. A number of clinical trials with a variety of tumour types have 
been completed, initially starting with intratumoural injection (Ganly et al, 2000) 
and then progi*essing to intraperitoneal (Vasey et al, 2002), intra-arterial/hepatic 
artery (Reid et al, 2001) and finally intravenous administration (Nemunaitis et al, 
2001) in patients with metastatic carcinoma. The virus was well tolerated at doses 
up to 1x10'^ pfu, with flu-like symptoms being the most common toxicities. Not 
surprisingly these symptoms were greatest in patients receiving intravascular 
treatment. Neutralising antibodies increased in all patients, regardless of dose, 
route of administration or tumour type. Having established safety, two phase II 
trials were conducted to assess the efficacy of ONYX-015 in head and neck
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cancer (Kim et al, 1998; Nemunaitis et al, 2000). 40 patients were recruited and 
tumours were treated aggressively with repeated injections, but 87% did not 
objectively respond. Also, there was no conelation between evidence of 
antitumoural activity and neutralising antibody levels, at baseline or following 
treatment.
Oncolytic viruses have great potential as combination therapy with standard 
chemotherapy dmgs. Agents that act by different mechanisms should make the 
emergence of resistant disease less likely. Also the toxicities associated with these 
agents would be different, thus allowing safe combination treatment. The most 
encouraging clinical results using ONYX-015 in head and neck cancer have come 
from trials combining it with standard chemotherapy. A phase II trial of a 
combination of intratumoural ONYX-015 injection with cisplatin and 5- 
fluorouracil in patients with recurrent HNSCC concluded an objective response in 
63% of patients (Kliuri et al, 2000). Also, the length of time to tumour progression 
for the injected tumours was improved. It is notable that there was no correlation 
between tumour response and baseline tumour size, baseline neutralising antibody 
titre, p53 gene status or prior treatment. 46% of patients reported grade 3 (severe) 
and 14% grade 4 (life-threatening) adverse events. The most common adverse 
reaction was injection site pain. A phase III trial combining ONYX-015, cisplatin 
and 5-fluorouracil was started; however in June 2003 all ONYX-015 programmes 
were discontinued in order to redirect resources towards a different line of 
research.
1.6 HERPES SIMPLEX VIRUS
Eight distinct herpes viruses have been identified (Table 4). They are all 
characterised by typical herpes particle morphology. The genome is typically
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large, consisting of a single molecule of double stranded DNA (dsDNA), ranging 
in size between 120 and 250 kb. Also they have the ability, following productive 
infection, to produce disease as well as enter a latent phase in some host cells. 
This latent phase allows survival of the viral genome tliroughout the lifetime of 
the infected individual and the ability to re-enter the productive phase.
Table 4: HERPES SIMPLEX VIRUSES
Herpes Simplex Virus Type-1 HSV-1 Cold sores
Herpes Simplex Virus Type-2 HSV-2 Genital ulcers
Varicella-Zoster virus VZV Chicken pox/Shingies
Epstein Barr Virus EBV Glandular fever
Cytomegalovirus HCMV Congenital anomalies
Human Herpesvirus 6 HHV-6 Fever/fits/rash in infants
Human Herpesvirus 7 HHV-7 Fever/fits/rash in infants
Kaposi’s sarcoma Herpesvirus KSHV,HHV-8 AIDS related Kaposi’s 
Sarcoma
1.6.1 HSV-1 VIRION AND GENOME
HSV-1 is a human neurotropic virus. The morphological structure of the 
infectious virus particle, the virion, is characterised by a central icosahedral 
capsid, containing the core dsDNA genome. More than 50% of the HSV genes are 
known to code for proteins that make up the virion structure (Figure 7). The 
capsid is surrounded by the tegument, which in turn is surrounded by a protein- 
containing lipid bilayer, the envelope. The tegument contains proteins involved in 
the induction of viral gene expression and the process of host cell synthesis shut 
off immediately post infection. The envelope is composed primarily of lipids
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derived from the host cell membrane, into which are inserted the HSV 
glycoproteins. Membrane glycoproteins mediate HSV entry into the cell, cell-to- 
cell spread, cell fusion and immune evasion.
Figure 7: HSV-1 VIRIO N
ENVELOPE
TEGUMENT
CAPSID
Electron Micrograph of a herpes simplex type 1 (HSV-1) virion, frozen in 
vitreous ice. The dsDNA genome is enclosed within the capsid.
(Department of Virology, Glasgow University)
The HSV-1 genome is a linear double stranded DNA duplex, 152 kb in length 
(Figure 8). There are two unique regions, long & short (termed U l & Us), which 
are linked in either orientation by internal repeat sequences (IRl & IRs). At the 
non-linker end of the unique regions are terminal repeats (TRl & TRs). 1 he DNA 
sequencing of the HSV-1 genome was completed in Glasgow, Scotland in 1988 
(McGeoch et al, 1988). There are up to 81 genes, of which about half are not 
essential for growth in cell culture. Once these non-essential genes have been 
deleted, 40-50 kb of foreign DNA can be accommodated within the virus. Most 
genes encoding proteins are located in the long or short regions, and they are 
named according to their location within L or S. For example, the US6 gene 
encodes glycoprotein D, a membrane glycoprotein involved in virus entry. Three 
main classes of HSV-1 genes have been identified, namely the immediate-early 
(IE or alpha) genes, early (E or beta) genes & late (L or gamma) genes. The ‘a’
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sequence is present as a direct repeat at the genomic termini and as an inverted 
repeat at the L-S junction.
Figure 8: HSV-1 VIRAL GENOME
T R l IRl IR s
Us
TRs
TRl Long terminal repeat
IR l Long internal repeat
IRs Short internal repeat
T R s Short terminal repeat
UL Unique long region
US Unique short region
1.6.2 HSV-1 REPLICATION
The HSV lytic cycle encompasses the primary infection of host cells and viral 
DNA replication in epithelial cells. During the course of its normal life cycle HSV 
must infect and replicate in at least two cell types, epithelial and neuronal.
HSV binds to the cell surface of host cells using glycoproteins. A number of 
glycoproteins are then required to aid penetration of the virus, including gB, gD, 
gH and gL (Cai et al, 1988; Ligas et al, 1988; Forrester et al, 1992). The vims 
penetrates the cell by fusion of the virus envelope with the cell plasma membrane 
(Shukla et al, 2001). Virus capsids are then transported to the nuclear pore and 
DNA is released into the nucleus to allow gene expression (Batterson et al, 1983). 
Replication is facilitated by the preferential production of viral proteins, at the 
expense of host cell gene expression (Zelus et al, 1996). HSV inhibits host gene
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transcription and RNA processing, and destabilises host and viral inRNAs (Schek 
et al, 1985). Within 3 hours post-infection, HSV-DNA replication is detected in 
the nucleus (Roizman et al, 1964).
Infected cell proteins (ICP), virion proteins (VP) and Virion molecular weight 
(Vmw) are the major nomenclatures for HSV proteins. Following infection of 
cells, lytic replication is regulated by a coordinated sequence of gene 
transcription. Vmw65, a tegument structural protein, activates immediate-early 
(IE) genes (ICPO, ICP4, ICP22, ICP27, ICP47), which transactivate the 
production of early (E) genes. The early genes encode proteins for nucleotide 
metabolism and DNA replication. Late genes are activated by the early genes, and 
code for structural proteins.
Newly synthesised DNA is cleaved into unit-length molecules and packaged into 
virions. Capsids containing DNA attach to the nuclear surface of the iimer nuclear 
membrane, at sites where viral glycoproteins and tegument proteins have 
accumulated, and ai*e rapidly enveloped. The virions accumulate in the 
endoplasmic reticulum and are transported into the extracellular space. 
Controversy remains over the exact intricacies of virus maturation and egi'ess. 
Following egi’ess, mature virions are capable of infecting neighbouring cells, 
either via the extracellular space or through cell-to-cell spread.
There are a number of protective host cell responses to HSV infection, which need 
to be overcome for successful viral replication and pathogenesis. A number of 
viral proteins, including virion host shut off (vhs) and ICP34.5, are integi*al in 
blocking these innate host cell reactions. Infected cells try to inhibit viral 
replication and, following the induction of a stress response, pro-apoptotic
55
pathways are activated to modulate virus spread. Another cellular response is the 
activation of protein kinase R.
A tegument protein, virion host shutoff (vhs), induces degradation of cellular and 
viral RNA early in infection (Read et al, 1983; Kwong et al, 1988; Krikorian et al, 
1991). The immediate early protein, ICP 27, blocks splicing of cellular mRNA. 
This reinforces the shutoff of cellular protein synthesis, initiated by vhs. Viral 
proteins gD, g j and protein kinase US3 play important roles in blocking 
programmed cell death induced by exogenous agents or by viral products. 
Activation of protein kinase leads to phosphorylation of the a subunit of the 
translation initiating factor eIF-2, and total protein synthesis shutoff, thereby 
preventing viral replication. HSV-1 has evolved a mechanism to evade this, by 
precluding host cell protein synthesis shutoff (Chou et al; 1992). ICP 34.5 binds to 
protein phosphatase 1 and redirects it to dephosphorylate eIF-2a, insuring 
uninterrupted synthesis of viral proteins (Chou et al, 1995; He et al, 1997). This 
pathway has only been demonstrated in vitro in one neuroblastoma cell line SK- 
N-SH.
1.6.3 LATENCY AND REACTIVATION
HSV has two unique biological properties that influence human disease. These are 
the capacity to invade and replicate in the central nervous system, and the capacity 
to establish a latent infection. Latency is the persistence of the virus in a host cell 
in a non-infectious forai. Following infection of nerve endings HSV-1 is 
transported to the nuclei of sensory ganglia by retrograde movement (Stevens et 
al, 1971). In most infected sensory neurones, the viral genome remains in an 
episomal state for the entire life of the individual. In contrast to the lytic pathway, 
viral gene expression is almost completely repressed during latency, and so
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neuronal lysis is prevented. This reduced gene expression helps to diminish 
recognition of infected cells by the immune system. Transcription therefore only 
occurs from a single area of the genome and results in a family of RNA 
molecules, latency-associated transcripts (LATs). The LAT locus is located in the 
long internal and terminal repeats (Perng et al, 1996). The exact mechanisms 
whereby HSV establishes latency, along with the integrated roles of LATs remain 
unclear.
Reactivation o f HSV from ganglia results in the appearance o f infectious virus at 
the site of the initial infection. It can occur following local or systemic non­
specific stimuli including physical or emotional stress, pyi’exia, UV light, 
systemic illness, tissue damage and immunosuppression. A number of different 
viral gene products, including thymidine kinase, are thought to be involved in this 
process, but the exact pathways remain unclear (Coen et al, 1989).
1.6.4 HSV-1 HISTOPATHOLOGY
Histopathological characteristics of a primary or recurrent HSV infection reflect 
virus-mediated cellular death and associated inflammatory response. A vesicular 
fluid forms between the epidermal and dermal layers, and contains large quantities 
of virus along with cellular debris and inflammatory cells. Shallow ulcers replace 
the vesicles when mucous membranes are infected. There is usually an intense 
inflammatory reaction in the dermis.
HSV infected cells lose intact plasma membranes and form multinucleated giant 
cells. Characteristically the cells balloon with membrane modifications and loss of 
matrix binding proteins on the cell sirrface. Also cytoskeletal destabilisation, 
nucleolar alterations and chromatin margination, aggregation or damage occur 
(Avitabile et al, 1995; Heeg et al, 1986; Roizman et al, 1996). This viral
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destruction of cells is generally believed to occur through a necrotic route. It is 
well documented that HSV-1 blocks apoptosis. This programmed cell death is 
characterised by morphological and biochemical changes that include cell 
slrrinkage, membrane blebbing, nuclear condensation and fragmentation of 
cliromosomal DNA (Aubert et al, 1999; Aubert et al, 1999 Galvan et al, 1999; 
Koyama et al, 1997; Zachos et al, 2001; Zhou et al, 2000).
1.6.5 HSV-1 PATHOGENESIS AND CLINICAL FEATURES 
The pathogenesis of human HSV depends on close contact between a 
seronegative individual, and one who is actively excreting HSV. The virus must 
come in contact with mucosal surfaces or broken skin for infection to be initiated. 
A virion or capsid is transported retrograde by neui'ones to the dorsal root ganglia 
where, latency is established. Once latency is established, a reactivation stimulus 
can cause the virus to again appear as skin vesicles or mucosal ulcers. Infection 
with HSV-1 usually occurs in the oropharyngeal mucosa, as the trigeminal 
ganglion becomes colonised and harbours latent virus.
HSV infection in a healthy immunocompetent individual results in non-specific 
and specific immune responses. An inflammatory reaction occurs, and parallels 
viral replication. Specific immune responses in humans are delayed, and develop 
7-10 days post infection. Cytotoxic T lymphocytes, CDS’"' cells, and helper T 
lymphocytes, CD4^ cells have been shown to be important in providing protection 
fi'om an HSV viral challenge, and to reduce viral replication. CD8^ cells are 
important in resolving cutaneous disease (Leung et al, 1984). Neutralising 
antibodies generally appear 2-6 weeks after infection and persist for the lifetime 
of the host. Humoural immunity does not prevent either recurrences or exogenous
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reinfection, whereby an individual is reinfected with a different strain of HSV 
(Timbury, 1991).
Primary HSV-1 infection in humans is usually asymptomatic. The incubation 
period ranges from 2-12 days, with a mean of approximately 4 days. Neutralising 
antibodies peak at approximately 3 weeks post infection. Symptomatic primary 
infection often presents with intraoral gingival lesions and sometimes pharyngitis 
with associated pyi'exia, malaise, cervical lymphadenopathy and odynophagia. 
Recurrent infections typically present with lip vesicles which progress to pustular 
or ulcerative lesions. Other cutaneous HSV-1 infections occur including eczema 
heipeticum and herpetic whitlow. HSV infections can also affect the eye causing 
conjunctivitis and keratitis.
The most serious HSV infection is encephalitis. The mortality if untreated exceeds 
70%, and only 2.5% of patients who survive regain normal neurological functiorr 
(Ward et al 1994). No clinical signs are pathognomonic for HSV encephalitis. The 
diagnosis should be considered in any ill patient with fluctuating levels of 
consciousness, pyrexia, abrromial CSF profile and focal neurological signs, in the 
absence of other causes. Prompt neurodiagnostic procedures, along with 
supportive and systemic treatment are imperative.
1.6.6 HSV-1 TREATMENT
Acyclovir (9-[2-hydroxyethoxymethylj guanine), a synthetic acyclic purine 
nucleoside analogue, is the standard treatment for HSV infections. Viral 
thymidine kinase converts acyclovir to acyclovir rnorrophosphate. The host cell 
enzymes convert the monophosphate to the diphosphate and therr to the active 
compound, acyclovir triphosphate. This inlribits HSV DNA replication. Viral 
thymidine kinase has a much greater affinity for acyclovir triphosphate than does
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mammalian thymidine kinase. Consequently acyclovir triphosphate only 
accumulates in virus-infected cells.
1.7 HSV1716: ONCOLYTIC HERPES SIMPLEX VIRUS
HSV1716 is an avirulent HSV-1 mutant with a 759 bp deletion in both copies of 
the RLl gene (MacLean et al, 1991). The long repeat regions of the wild type 
HSV-1 genome contain the diploid RLl gene, whose protein product ICP34.5 is a 
major determinant o f pathogenicity (Ackermami et al, 1986; Chou et al, 1990, 
MacLean et al, 1991, McKie et al, 1994). HSV1716 was first isolated following a 
spontaneous mutation of HSV 1 7 \ while trying to identify the precise regions of 
the HSV genome involved in pathogenicity. An avirulent mutant HSV1714 was 
found to have a deletion in both copies of the Bam HI fragment of the long repeat 
region. This is in addition to deletions in the four Xbal sites of the unique long 
region and a thymidine kinase negative phenotype. The long repeat deletion of 
HSV 1714 was introduced into a totally wild type genome (17^) to produce 
HSV 1716, which is avirulent and is as efficient as wild type HSV in thymidine 
kinase synthesis. Thymidine kinase is essential for acyclovir antiviral medication 
efficacy. The deletion in HSV1716 removes most of the RLl gene, including the 
initiating ATG, and the mutant fails to make ICP34.5 (McKay et al, 1993). 
HSV1716 has been characterised as a selectively replication competent virus and 
a potential novel cancer therapy. It fails to replicate in neurones of the central 
neiwous system or peripheral nervous system (MacLean et al, 1991; McKie et al, 
1998; Robertson et al, 1992). Also it does not replicate in terminally differentiated 
cells or cause encephalitis following intracerebral inoculation of mice (MacLean 
et al, 1991). However its replication in many tissue culture lines matches that of 
the parental wild type HSV-1 strain 17. In general, dividing cells support
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replication of HSV1716 and non-dividing cells cannot (Brown et al, 1994). These 
findings highlight the potential for targeting tumour cells, with an aim of 
oncolysis and sparing of the surrounding normal tissue
1.7.1 HSV1716 REPLICATION
A) IGF 34.5
The mechanisms whereby HSV1716 selectively replicates in and lyses rapidly 
dividing cells are not fully understood. ICP 34.5-cellular interactions have been 
shown in vitro to be cell type and cell state, or differentiation state, dependent 
(Brown et al, 1994). For example, HSV1716 does not replicate in confluent 
mouse fibroblast (3T6) cells, and the lack of ICP 34.5 results in a defect in 
maturation and egress of virus from infected cells (Brown et al, 1994). As 
described in section 1.6.2, ICP 34.5, in certain cells, interacts with protein 
phosphatase 1 to preclude host cell protein synthesis shutoff. Also, a different ICP
34.5 null mutant has been shown to cause shutdown o f protein synthesis, before 
completion of the viral replicative cycle, in the human neuroblastoma cell line 
SK-N-SH (Chou et al, 1995). However, further work with HSV1716 has shown it 
to cause tumour cell kill by lytic replication. Premature host cell shutoff via the 
PKR pathway is not induced in vivo by HSV1716 in most cells, inespective of 
type or state (McKie et al, 1996; Markovitz et al, 1997; Harland et al, 2003). 
Other viral-host cell interactions are therefore involved.
B) PROLIFERATING CELL NUCLEAR ANTIGEN
Following HSV-1 infection a cell cycle control protein, proliferating cell nuclear 
antigen (PCNA), is recruited to sites of DNA repair in the cell nuclei. Here it 
forms a complex, directly or indirectly, with ICP 34.5 (Brown et al, 1997). PCNA 
has important fimctions in DNA repair and replication (Prelich et al, 1987; Shivji
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et al, 1992). ICP 34,5 concentrates in vivo in the cell nucleus with PCNA at early 
stages in the infection, and subsequently accumulates in the cytoplasm. The ICP 
34.5-PCNA complex allows HSV DNA replication to continue. This is 
particularly pertinent to nondividing cells and HSV encephalitis. The intricacies 
are not fully understood as other cell-cycle regulation proteins are involved. 
PCNA is regulated by a variety of proteins and it is believed that this regulation 
may act as a switch between the processes of DNA repair and replication (Harland 
et al, 2003).
A 63-amino acid region of ICP 34.5 shares significant homology with two cell- 
cycle regulation proteins; mouse myeloid differentiation protein (MyD116) and 
growth aiTest and DNA damage protein 34(GADD 34) (Lord et al, 1990; Fornace 
et al, 1989; McGeoch and Barnett, 1991). Interestingly the same region shares 
significant homology with part of an African swine fever virus protein, which is 
also a detenninant of virulence (Sussman et al, 1992). The functions of both 
MyDl 16 and G ADD 34 are not fully understood but may be involved in blocking 
giowth and DNA replication after damage, and the genes may act as tumour 
suppressor genes. The ability of ICP 34.5 to preclude premature shutoff of protein 
synthesis, in SK-N-SH neuroblastoma cells, is preseiwed when there is in-frame 
substitution of the homologous domain of ICP 34.5 with the corresponding 
domain of MyDl 16 (He et al, 1996). In vivo PCNA complexes with the region of 
MyDl 16 that shares homology with ICP 34.5 (Brown et al, 1997). The 
homologous regions of MyDl 16 and G ADD 34 could also regulate the DNA 
replication mode of PCNA.
Overall the pathways are complex and not fully understood. ICP 34.5 is certainly 
a multifunctional protein, which can overcome a block in protein synthesis
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induced as an antiviral defence mechanism in certain cells. Its primary function in 
vivo, relevant to the HSV1716 phenotype, is its interaction with PCNA to 
overcome the block in DNA replication in nondividing cells. PCNA levels are 
high in tumour cells, and its correlation with disease stage and poor prognosis in 
head and neck cancer is well documented (Sarac et al, 1998; Liu et al, 2003; 
Krecicki et al, 1999). Due to the high PCNA levels ÏCP34.5 is not needed for 
HSV replication, ergo HSV1716 replication.
1.7.2 IN  VIVO STUDIES OF HSV1716
Having characterised HSV1716 as a potential novel cancer therapy, studies were 
performed to establish a safety and efficacy profile. Early in vivo experiments 
showed intracerebral inoculation of wild type HSV 17^, at a dose of less than 10 
pfu to cause encephalitis in immune competent BALB/c mice. In comparison, 
HSV1716 doses of 10  ^ pfu resulted in no evidence of viral replication or 
encephalitis (MacLean et al, 1991). Another study confirmed avirulence following 
intracerebral inoculation of HSV1716 in immunocompromised SCID mice (Valyi- 
Nagy et al, 1994). The safety profile was supported fui-ther by a study using G207, 
a different ICP 34.5 mutant of HSV-1, which confirmed avirulence on 
intratumoural inoculation of gliomas in a murine model (Mineta et al, 1995). 
HSV1716 was shown to be effective in selective lytic replication in a variety of 
tumour types, prior to progressing to clinical trials. Improved survival was seen 
following intratumoural injection of medulloblastoma tumours in a murine model 
(Lasner et al, 1996). Significant tumour regression and improved survival was 
seen following HSV1716 intratumoural injection of melanoma tumour deposits 
grown in the brains of immunocompetent C57B mice (Randazzo et al, 1995). 
Viral replication was confirmed, and seen to be restricted to tumour cells and not
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to involve the surrounding brain tissue. Similar findings were seen when 
intracerebral deposits of human embryonal carcinoma cells were injected with 
HSV1716 (Kesari et al, 1995). Effective oncolysis of malignant mesothelioma, 
with tumour regression and improved survival, was seen when intraperitoneal 
deposits were injected with HSV1716 (Kucharczuk et al, 1997). A murine model 
involving subcutaneous human melanoma was also successful in showing 
selective replication and efficient oncolysis (Randazzo et al, 1997). 
Immunohistochemistry confirmed the viral replication to be restricted to the 
tumour cells.
HSV1716 had been characterised as a selectively replication competent oncolytic 
virus, with an established safety profile. Showing efficacy against a variety of 
tumour types had expanded the potential scope of HSV1716 as a novel cancer 
therapy. With this competent profile it was possible to progress to human clinical 
trials using HSV1716.
1.7.3 CLINICAL STUDIES OF HSV1716
A) FIRST MALIGNANT GLIOMA PHASE I TRIAL
The first clinical trial involving HSV1716 was a phase I toxicity study in patients 
with glioblastoma multiforme (Rampling et al, 2000). The main objective of the 
study was to demonstrate safety at a dose at which therapeutic activity was 
possible. Glioblastoma is a very aggressive disease that is universally fatal and 
has a median survival of approximately 9 months.
In planning the study, a difficult decision had to be addressed regarding the 
dosages of virus to be administered. In the development of conventional cytotoxic 
chemical agents, a safe starting dose is usually derived from animal experiments. 
Dose escalation protocols are designed with mandatory toxicity end-points. This
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approach cannot be applied in the same way to a replication competent biological 
agent. Following inoculation the final titre of virus could be several orders of 
magnitude higher than the input dose. Biological therapies may produce non­
specific and sporadic toxicities, which are not clearly dose related. The adverse 
effects of other gene therapy agents have sometimes been unexpected with regard 
to the preclinical models, and in one instance fatal (Raper et al, 2002; Lehnnan,
1999). In 1999 an 18-year-old man died of multi-organ failure during a gene 
therapy trial. He had received liver-directed gene transfer to correct partial 
ornithine transcarbamylase (OTC) using an adenovirus vector. Unpredictable side 
effects and iimnunological effects give justification for the prudent approach of 
the Gene Therapy Advisory Committee (GTAC), which oversees gene therapy 
trials in the UK.
As HSV1716 had the potential to replicate in tumours, it was estimated that 20% 
of infectious particles could result in a productive infection and each infected cell 
could give a burst size of 100 pfu. It was then decided that the maximum dose in 
the first trial, legislated by GTAC, would be 10  ^pfu.
Patients recmited into the study had recurrent high-grade gliomas and had 
exhausted all other conventional therapies, including surgery, radiotherapy and 
chemotherapy. HSV1716 was injected into the tumours by stereotactic injection. 
The first three patients were injected with HSV1716 at a low dose of 10  ^ pfu, 
followed by tlnee at lO"^  pfu and three at 10  ^ pfu Patients were observed in the 
hospital and followed up in the clinic.
The study demonstrated that HSV1716 could be injected intratumourally in 
inununocompromised patients with glioblastoma, in doses up to 10  ^pfu with no 
evidence of associated toxicity. Eight patients were seropositive for HSV and
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there were no significant changes in their IgM or IgG antibody levels. One patient 
was seronegative and did not seroconvert. Post-injection tissue was obtained horn 
three of the patients during subsequent tumour resection and from two of the 
patients at post-mortem. There was no evidence o f encephalitis and tissue cultures 
were negative for HSV. Immunohistochemical analysis showed no significant 
immunoreactivity of tumour cells or adjacent brain tissue for HSV-1 using 
monoclonal antibodies. There was no evidence of HSV1716 or wild type genomes 
by PGR. Tissue cultures were negative.
The study was successfril in establishing an early safety profile. It had not been 
designed as an efficacy model, however the outcomes of four o f the patients are 
notable (Table 5). At the time of viral injection these patients had a life 
expectancy in the region of 5-6 months.
Table 5: FIRST GLIOMA TRIAL - PATIENT OUTCOMES (Updated to 
October 2005)
1 22 M :: 94+ (PATIENT STILL ALIVE)
2 48 M 10
3 62 M 3
4 34 M 26
5 41 M 6
6 63 M 6
7 37 M 87* (PATIENT STILL ALIVE)
8 65 F 38
9 56 F 2
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B) SECOND MALIGNANT GLIOMA PHASE I TRIAL
The second clinical trial with HSV1716 was a proof of principle study 
(Papanastassiou et al, 2002). hi the first study there was no formal analysis to 
assess viral replication. A primary objective in the second study was to 
demonstrate that the vims survives and replicates following intratumoural 
injection.
Twelve patients with recurrent and newly diagnosed high-grade glioma were 
recmited. They received an intratumoural injection of 10  ^pfu of HSV1716. Four 
to nine days post-inoculation the tumours were removed and assayed for evidence 
of viral replication. Nine patients received radiotherapy or chemotherapy after 
surgery.
No patients had any viral associated adverse reactions. In two patients, infectious 
HSV1716 was recovered from the injection site at titres in excess of the input 
dose. The same two patients were seronegative for HSV-1 pre-injection. They 
both seroconverted and initial changes in specific IgG were detected at 19-21 days 
post-injection.
HSV DNA was detected by PCR at the sites of inoculation in 10 patients and at 
distal tumour sites in four. A tumour biopsy taken at post mortem fr'om one of the 
patients, 251 days post-injection, was PCR positive for HSV DNA. 
Immunohistochemistry analysis of tumour tissue for HSV antigen was positive 
from two patients.
The trial was successful and gave further support to the safety profile of 
HSV1716. It was able to conclude that HSV1716 replicates in high-grade glioma 
without causing toxicity in both HSV-seropositive and HSV-seronegative
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patients. The sm*vival of patients post-inoculation was variable, with a maximum 
of 26 months.
C) THIRD MALIGNANT GLIOMA PHASE I TRIAL
One further phase I study was conducted involving patients with high-grade 
glioma (Harrow et al, 2004). Twelve patients with recuiTent or newly diagnosed 
disease were recruited and underwent maximal tumour resections. HSV1716, at a 
dose of 10  ^ pfu, was then injected into the resulting tumour cavity with the intent 
of infecting residual tumour cells and testing safety when injected into brain 
adjacent to tumour.
There was no clinical evidence of toxicity associated with the administration of 
HSV1716. Longitudinal follow-up allowed assessment of overall survival 
compared to that o f similar patients not treated with HSV1716. One patient 
remains alive and clinically stable at 47 months post surgery and HSV1716 
injection. In the latter patient, radiological imaging has demonstrated a reduction 
of residual tumour following surgery and HSV1716 inoculation. This is despite no 
subsequent medical intervention. See Table 6 for summary of patient outcomes. 
These three trials have established a safety profile for the intratumoural injection 
of HSV1716 in patients with high-gi'ade glioma. In addition there have been 
promising signs of viral replication and patient survival. A European wide Phase 
III trial has been approved by the regulators (EMEA, MHRA, GTAC) and will 
commence in March 2006..
D) MELANOMA PHASE I TRIAL
A phase I trial was conducted involving melanoma patients (MacKie et al, 2001). 
Five patients were recmited and received intratumoural injections of subcutaneous 
nodules of metastatic melanoma. Two patients each received one injection, two
68
Table 6: THIRD GLIOMA TRIAL - PATIENT OUTCOMES (Updated to 
October 2005)
1 61 M 37
2 43 M 6
3 43 M 9
4 40 M 15
5 49 M 8
6 58 F 3
7 41 M 32
8 53 M 11
9 40 M 14
10 33 F 47* (PATIENT STILL ALIVE)
11 66 M 12
12 55 M 11
received two injections and one received four injections of H SV I716, at a dose of 
10  ^pfu. Biopsies were taken at various intervals.
There were no adverse reactions to the HSV1716 injections. All patients were 
HSV seropositive and there were no significant changes in their IgM and IgG 
titres post-inoculation.
In one patient, flattening of previously palpable tumour nodules was seen 21 days 
after two direct injections of HSVI716. In all tlri’ee patients who received two or 
more injections there was microscopic evidence of tumour necrosis. 
Immunohistochemistry analysis showed evidence of viral replication within the 
limits of the tumour mass. There was no antigen staining in the adjacent normal 
connective tissue and the basal layer of the epidermis. This latter result suggested 
that the normal melanocytes were antigen-ffee. There was no evidence of 
infectious virus in any of the samples.
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This trial strengthened the safety profile of HSV1716. It demonstrated that 
HSV1716 replicates and cause necrosis in melanoma cells. The fact that all 
patients were seropositive for HSV indicates that the replication competency of 
HSV1716 is not blocked by previous exposure to HSV.
1.8 OTHER ONCOLYTIC HERPES SIMPLEX VIRUSES
1.8.1 G207
G207 is a different mutant of HSV-1. It is a replication competent oncolytic virus 
and laboratory studies have demonstrated cytotoxicity against HNSCC. G207 was 
derived from HSV-1 strain F. It has multiple mutations including deletions at both 
loci of the ICF34.5 gene and insertion of a LacZ reporter gene into the IGF 6 gene 
(Mineta et al, 1995). G207 has a positive thymidine kinase phenotype. The ICF6 
gene encodes the large subunit of HSV ribonucleotide reductase, and loss of its 
expression decreases the ability of G207 virus to proliferate in nondividing cells. 
The multiple mutations of G207 are thought to minimise the chance of reversion 
to wild-type virus, but the tumour is less replication competent in tumour cells.
In vitro and in vivo studies showed G207 to infect and cause efficient lysis of 
HNSCC (Carew et al, 1999; Chahlavi et al, 1999). Animal studies involved direct 
intratumoural injections into murine flank tumours as well as selective intra- 
arterial perfusion of oral cavity tumours. All experiments showed inhibition of 
tumour growth.
A safety profile has been established for G207 following intratumoural injections 
of patients with high-grade glioma (Markert et al, 2000). Doses between 10  ^pfu 
and 3 X 10  ^ pfri were injected. These high doses are required due to the low 
replication efficacy. No adverse reactions specific to G207 were observed. There 
have been no clinical trials involving G207 and head and neck cancer patients.
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1.8.2 NV1020
NV1020 is another multi-mutated HSV-1 oncolytic virus, which has shown 
cytotoxicity to HNSCC in vitro and in vivo. It has deletions of one copy of ICP
34.5 and the virulence-associated virion gene, UL 56. It also has a deletion in the 
thymidine kinase locus. As NV1020 was originally designed as a potential HSV 
vaccine, a fragment of HSV-2 DNA is inserted into the UL/S junction. This 
junction also contains an exogenous copy of the HSV-1 thymidine kinase gene 
under control of the strong ICP 4 promoter, in addition to a duplication of the 
UL5/6 sequences.
In vitro studies showed NV1020 to be highly cytotoxic to five human HNSCC 
lines (Wong et al, 2001). Tumour regression was seen following injections into 
flank tumours in a murine model. Biopsies from tumours identified areas of 
necrosis 24 hours post-injection.
A phase I clinical trial involving hepatic artery administration of NV1020 in 
patients with intrahepatic colorectal métastasés has been performed (Kirn et al, 
2001). The published results are awaited. No clinical trials have been performed 
involving head and neck cancer patients.
1.9 COMBINING THERAPIES FOR HEAD AND NECK CANCER
Combining therapies gives a number of potential advantages. For certain stages of 
a range o f cancers, combinations of radiotherapy and chemotherapy, surgery and 
radiotherapy or surgery and chemotherapy have proved to be more effective. 
Chemotherapy regimens usually involve a combination o f agents. Using a 
combination o f agents gives potential for using lower doses, maximising the 
therapeutic effect and minimising side effects. Combining therapies also gives 
potential for enhanced effects, and this can be additive or synergistic. Synergism
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occurs when the effects of the combined agents are equal to or greater than the 
sum of the effects of the agents in isolation. A phase II clinical trial of 
intratumoural ONYX-O15 inoculation in combination with cisplatin and 5- 
fluorouracil in patients with recurrent head and neck cancer demonstrated tumour 
selective augmentation of chemotherapy efficacy by ONYX-015 (Kliuri et al,
2000). Patients were recruited with more than one head and neck tumour mass, 
allowing one mass to be free from viral injection and to act as an internal control. 
The trial was unable to conclude a survival advantage.
Unfortunately randomised trials using combination chemotherapy in head and 
neck cancer failed to show improved survival compared with single agent therapy 
(see section 1.1.8 C). This emphasises the need for the development of novel 
therapies. These therapies could potentially be used in combination with 
conventional chemotherapy agents.
In vivo cytotoxicity studies involving G207 combined with cisplatin showed 
additive tumouricidal effects in one of two established human HNSCC murine 
flank tumours. There was no enlianced kill in the other tumour model, and it was 
noted that the cell type involved was less sensitive to cisplatin. The G207 and 
cisplatin appeared to be acting independently.
In vitro and in vivo studies with non-small cell lung cancer have shown 
synergistic effects between HSV1716 and mitomycin C (Toyoizumi et al, 1999). 
The synergistic dose of mitomycin-C neither augmented nor inhibited viral 
replication in vitro. Additive effects were found combining HSV1716 with cis- 
platinum II, methotrexate or doxorubicin. No laboratory studies have been 
performed looking at the effects of HSV1716 on HNSCC in isolation or in 
combination with conventional chemotherapeutic agents.
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1.10 AIMS OF RESEARCH STUDY
The aims of this research study were:
1. To determine whether HSV1716 would replicate in and kill head and neck 
squamous cell lines,
2. To determine if the cytotoxic effects in vitro were enlianced when combined 
with the conventional chemotherapeutic agent cisplatin.
3. To cany out a phase I clinical safety trial involving the preoperative 
intratumoural injection of HSV1716 in patients with oral squamous cell 
carcinoma.
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CHAPTER 2
MATERIALS
MATERIALS
2.1 CELLS
Baby hamster kidney: 21 clone 13 (BHK) cells (MacPherson and Stoker, 1961) 
and mouse embryo fibroblast (3T6) cells (Todaro and Green, 1963) were obtained 
from the European collection of Cell Cultures (ECACC).
HNSCC cell Lines UM-SCC 14C (Grenman et al, 1991), UM-SCC 22A and UM- 
SCC 22B (Carey et al, 1983) were kindly provided by Professor Gnus van 
Dongen, VU University Medical Centre, Amsterdam.
2.2 Cell culture media
BHK21/C13 cells were grown in BHK-21 medium (Invitrogen Ltd, Paisley, UK) 
supplemented with 10% newborn-calf serum (Invitrogen Ltd); 10% (v/v) tryptose 
phosphate broth; 10,000 lU/ml penicillin (Invitrogen Ltd); 10,000 UG/ml 
streptomycin (Invitrogen Ltd) and 250 UG/ml amphotericin B(Invitrogen Ltd).
3T6 cells were gi'own in Dulbecco’s modified eagles medium (Invitrogen Ltd) 
supplemented with 10% foetal calf semm (Invitrogen Ltd); 10,000 lU/ml 
penicillin; 10,000 UG/ml streptomycin and 250 UG/ml amphotericin B.
All HNSCC cell lines were gi'Own in Dulbecco’s modified eagles medium 
supplemented with 10% heat-inactivated foetal calf semm (30 minutes at 54°C); 
10,000 lU/ml penicillin; 10,000 UG/ml streptomycin; 250 UG/ml amphotericin B 
and 100 nM non-essential amino acids (Sigma, Dorset, UK).
Eagle’s medium containing 1% carboxymethyl cellulose , 10% new-born calf 
serum and 10% tryptose phosphate broth, (ETMC 10%),was used during the 
titration of vims stocks.
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2.3 VIRUSES
Wild-type HSV-1 strain 17"^ ' (Brown et a l, 1973) and HSV1716 (MacLean, A., et 
a l, 1991) were used for all laboratory studies. HSV1716, GMP grade, was 
prepared by Q1 Biotech, Glasgow, and used for clinical studies.
2.4 SOLUTIONS
2.4.1 AGAROSE GEL REAGENT
TBE: 0.04M Tris, 0.14% acetic acid (v/v), 2mM EDTA (pH 8.0)
2.5 CHEMICALS
All chemicals were of AnalaR grade and were obtained form BDH Chemicals 
Ltd, Poole, Dorset or Sigma Chemicals Ltd, Poole, Dorset. Exceptions were:
APS and Temed -  supplied from Bio-Rad laboratories.
Histoclear -  supplied by Fisher Chemicals 
Aqueous mounting medium -  Dako®, Faramount 
Platinum® Pjfr DNA polymerase, MgS0 4 -  hivitrogen
2.6 CYTOTOXICITY ASSAYS
Cell viability assays (MTS) were measured using CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (Promega, Southampton, UK). Readings were 
taken using a Dynatech MR5000 96 well plate reader.
2.7 HSV ANTIBODY DETECTION KIT
HSV IgM and IgG detection was performed using Elisa Kit, Virotech, 
Russelsheim, Germany.
2.8 HUMAN BLOOD AND TISSUE DNA EXTRACTION KIT
DNA was extracted from clinical trial patients’ blood and tissue biopsies using 
Nucleon® genomic DNA extraction kit (Amersham Biosciences,
Buckinghamshire, UK).
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2.9 IN-SITU HYBRIDISATION KIT
In-situ hybridisation was performed using Rembrandt® in situ hybridisation kit 
(Panpath, Amsterdam, Holland).
2.10 ANTIBODIES
In immunohistochemistry experiments, the primary monoclonal antibody to the 
HSV-1 strain Stoker was obtained from Abeam Limited, UK.
2.11 EQUIPMENT AND PLASTICWARE 
Invitrogen Ltd. Life Technologies Ltd. Paisley 
Nunc 1 ml cryotubes
Nunc 12 well tissue culture plates
Nunc 25 cnf, 75 cm^, 175 cn f tissue culture flasks
Tissue culture dishes (35mm, 60 mm)
Fisher Scientific UK, Loughborough, Leicestershire 
Coming Incorporated 850 cm^ tissue cultine roller bottle 
Greiner Bio-One Ltd. Stonehouse, Gloucestershire 
Eppendorf tubes 
Universal bottles 
Bijoux bottles 
96 well plates 
Sterile pipettes
2.12 OTHER MATERIALS
2.12.1 CENTRIFUGES
Volumes <1.5ml, up to 13,000rpm:
Volumes L5ml-45ml, up to 13,000rpm:
Micro-centrifrige 
Beckman Centrifuge
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2.12.2 MICROSCOPE
Images of cells were captured under a DMLB Fluorescent microscope using a DC 
200 digital camera (Leica) and Leica IM 500 software.
78
CHAPTER 3
METHODS
3. METHODS
3.1 IN VITRO STUDIES
3.1.1 BHK21/C13 Cells
BHK21/C13 and 3T6 cells were grown in 850 cm^ tissue culture roller bottles 
containing 125 ml ETC 10 medium at 37®C for 3 days in an atmosphere of 95% air 
and 5% CO2. Washing the monolayers twice with HBSS and trypsin-EDTA, and 
resuspending the detached cells in 20 ml of the appropriate medium harvested the 
cells. The yield from a confluent roller bottle is approximately 1x10^ cells, which 
would give 100 confluent monolayers on 60mm diameter tissue culture dishes 
after an overnight incubation at 37^C.
3.1.2 HEAD AND NECK SQUAMOUS CARCINOMA CELLS
HNSCC cell lines were grown in 175 cm^ tissue culture flasks and haiwested 
under the same conditions. The yield of cells was deteimined as described by 
Freshney (1987) using an improved Neubauer counting chamber (Weber, 
England).
3.1.3 PASSAGING OF CELLS
T-175 flasks or roller bottles with 80-100% confluent monolayers were opened in 
a category 2 hood. The media was decanted and 22.5 ml of Hanks Balanced Salt 
Solution (HBSS) was poured over each monolayer and decanted after 30 seconds. 
Trypsin, stored in 2.5ml aliquots, was thawed from -20°C and mixed with 22.5ml 
Hanks Balanced Salt Solution (HBSS) to yield 10% (v/v) trypsin/HBSS solution 
in 25ml. One volume of Trypsin/HBSS solution was added to each monolayer and 
90% removed after 30 seconds. The cells detached and this was aided by 
incubation at 37°C. The cells were resuspended in 10-20ml of the appropriate 
gi'owth medium and used to seed further flasks or roller bottles.
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3.1.4 CRYOPRESERVATION OF CELLS
Confluent cell monolayers were harvested as described in section 3.2. The 
suspension containing cells for storage was pipetted into a universal container and 
spun at 2000rpm (Beckman centrifuge) for 10 minutes at 4^C. The supernatant 
was decanted and the pellet resuspended in 1ml of appropriate growth medium 
containing 10% DMSO (Sigma). This suspension was pipetted into 1.5 ml cryo- 
vials and stored overnight at -70°C. The cells were moved to a liquid nitrogen 
freezer for long-term storage.
3.1.5 TITRATION OF VIRUS STOCKS
The amount of infectious virus within a stock was quantitated as described by 
Brown and MacLean, 1997. Vims stocks were serially diluted 10-fold in ETCio. 
lOOpl aliquots were added to 85% confluent monolayers of BHK21/C13 cells on 
60mm petri dishes, from which the medium had been removed. The plates were 
incubated at 37°C for 1 hour, to allow adsorption of the virus onto the cells. The 
plates were washed twice with PBS, before overlaying with 5 ml ETMC 10 % and 
incubated at 31°C for 3 days. Monolayers were fixed and stained with Giemsa 
stain at room temperature for 2 hours. After washing, plaques were counted on a 
dissection microscope and virus titres calculated as pfu/ml.
3.1.6 MULTICYCLE GROWTH EXPERIMENTS
The growth kinetics of HSV1716 in HNSCC cell lines, UM-SCC 14C, UM-SCC 
22A and UM-SCC 22B, were determined by performing multicycle gi'owth 
experiments. For each HNSCC cell line, BHK21/C13 and 3T6 cells were also 
infected with HSV 1716, at a low MOI of 0.1 pfu per cell, and monitored over 72 
hours. A parallel experiment was also mn infecting the same cells with wild type 
HSV strain 17"^ .
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Cells were initially seeded in 35 min tissue culture plates at a density of 2 x lO'^  
cells per plate, in 2 ml o f the appropriate cell media. Following an overnight 
incubation at 37^C and removal o f the media, the cells were inoculated with 
HSV1716 or wild type HSV strain 17 .^ The viruses were diluted to 2 x 10  ^
p.f.u/ml and 100pi added to each plate (0.1 p.f.u/cell). The virus absorbed during a 
1 hour incubation at 37^C. Unabsorbed virus was washed off with 2 ml of 10% 
newborn calf serum/PBS. The plates were overlaid with 2 ml of the appropriate 
media and this marked 0 hours on the time-scale.
Virus samples were harvested at 0, 6, 24, 48 and 72 hours, by scraping the cell 
monolayers into the medium and transfening the suspension into a bijoux bottle. 
The samples were sonicated for 5 minutes and stored at -70°C until they were 
titrated.
The vims samples were titrated as described previously, and titres calculated at 
each time-point. The titres were plotted on a log graph scale with pfu/10^ cells on 
the y-axis and time (hours) on the x-axis.
3.1.7 MTS CYTOTOXICITY ASSAY
In vitro cytotoxicity was determined using a Celltitre 96® Aqueous One Solution 
Cell Proliferation Assay (Promega) in accordance with the manufacturer’s 
instructions. This solution contains an MTS tétrazolium compund, an analogue of 
MTT, which is bioreduced by cells into a coloured formazan product that is 
soluble in tissue culture medium. The production of fonnazan is proportional to 
the number of living cells; therefore the intensity of the produced colour indicates 
the viability of the cells.
Cell suspensions were prepared from 80% confluent T-175 flasks as described in 
section 3.1.3. Cells were seeded in 96-well plates at densities between 4-6 x 10^
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cells per well, depending on the cell type, in 100 pi volumes. All the perimeter 
wells were kept free and filled with sterile water to aid humidification during the 
experiments. After overnight incubation at 37°C, the media was removed from all 
wells and serial concentrations of HSV 1716 and/or cisplatin were added in 100 pi 
volumes. Six wells were prepared for each concentration. In all experiments, six 
control wells were prepared with cells and medium alone.
After 72 hours incubation at 37°C, all wells were aspirated dry and 100 pi of fresh
medium added. Six control wells were also prepared with 100 pi of media alone.
20 pi of MTS was then added to each well. Optical density readings were taken at 
480nm after 2-4 hours incubation at 3TC.
3.2 PHASE I CLINICAL TRIAL
3.2.1 ENROLMENT CRITERIA
A total of 20 patients with injectable oral squamous cell carcinoma were entered 
into the trial. Patients were recruited from the multi-disciplinary head and neck 
clinic at the Camiiesbum Unit, Glasgow Royal Infirmary.
Eligibility requirements included histologically confirmed oral squamous cell 
carcinoma, which was amenable to direct injection under local anaesthetic and 
appropriately treatable by complete surgical resection.
All patients had a Kamofsky Performance status of greater than or equal to 70% 
(Table 7), and were between 18 and 75 years of age. All patients had adequate 
haematological, renal and hepatic function. The maximum allowed blood 
creatinine was 1.5 mg/dL; maximum allowed aspartate transaminase (AST) and 
alanine transaminase was 2.5 fold the upper limit of normal; minimum allowed 
haemoglobin was 9 g/dL; minimum allowed white cell count of 3000/pl 
(neutrophils 1500/pl) and minimum platelet count of 100,000/pl.
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Patients with any active acute infection or who were HIV positive, pregnant or 
had received previous treatment with viral therapy were excluded from the trial. 
All patients gave written informed consent. The UK Gene Therapy Advisory 
Coimnittee (GTAC), and the Medicines Control Agency of the Department of 
Health and North Glasgow University NHS Trust approved the protocol.
Table 7: Karnofsky Performance Status Scale
100 Normal; no complaint; no evidence of disease
90 Able to carry on normal activity; minor signs of symptoms of disease
80 Normal activity with effort; some sign or symptom of disease
70 Cares for self; unable to carry on normal activity or do active work
60 Requires occasional assistance but is able to care for most personal needs
50 Requires considerable assistance and frequent medical care
40 Disabled; requires special care and assistance
30 Severely disabled; hospitalisation is indicated, although death is not 
imminent
20 Veiy sick; hospitalisation is necessary; active support treatment is necessary
10 Moribund; fatal processes progressing rapidly
3.2.2 HSV 1716
HSV 1716 is an oncolytic deletion mutant of HSV-1 strain 17^. It has deletions of 
both copies of the RLl gene and is unable to make the vimlence factor ICP 34.5. 
HSV 1716 is avirulent.
Q1 Biotech (Glasgow, UK) produced purified, sterile lots of HSV1716. The virus 
was tested for titre, sterility and safety and is Good Manufacturing Practice 
(GMP) grade. HSV 1716 is stored long-term at -196^C in a liquid nitrogen 
freezer. Vials were packaged in dry ice, in the short interval between removal 
from the freezer and patient injection.
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3.2.3 TREATMENT PROTOCOL
Pre-treatment evaluation included complete blood cell count with differential, 
coagulation screen, routine biochemistry profile, immunology screen, urinalysis, 
chest x-ray and electrocardiogram. All patients had an initial examination under 
anaesthesia during which the tumour was clinically staged, and a core biopsy 
taken to confirm the diagnosis of squamous cell carcinoma.
Once all the eligibility criteria had been met, the patients were allotted to one of 4 
groups, starting with group A. The injection protocols are shown in Table 8.
The patients were admitted to the nonnal head and neck surgical ward and fully 
informed and written consent was given. The patients were then prepared for the 
viral injections.
With the patient lying in a semi-recumbent position, the tumour and contralateral 
side of the mouth were re-examined under illuminated direct vision. An area of 
tumour was chosen for injection, which was most accessible to injection and 
would be easily identifiable following surgical resection. The tumour and the 
normal buccal mucosa on the contralateral side of the mouth were sprayed 5 times
Table 8: Patient grouns and in lection nrotocols1
GROUPA 5 72 HOURS
GROUPE 5 5X10  ^PFU 72 HOURS
GROUP C 5 5X10  ^PFU 24 HOURS
GROUP D 5 5X10' PFU 14 DAYS
with lignocaine, each spray delivering lOmg of lignocaine base. 5 minutes later 
the virus was thawed and the required dose aspirated into a syiinge in a 0.5 ml
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volume. A blue 23-gauge needle was introduced into the target tumour, and the 
syringe initially aspirated. This determined if the needle was in a blood vessel and 
avoided direct intravascular injection. The virus was injected while the needle was 
slowly withdrawn in order to distribute the volume equally along the needle tract. 
The same dose was then injected into a chosen site of buccal mucosa on the 
contralateral side of the mouth. This area was tattooed circumferentially with 4 
dots of Chinese ink to aid identification at the time of surgery.
Each patient was observed on the ward for the first 24 hours post-injection, to 
identify any symptom or sign of an adverse reaction. Toxicity was assessed using 
the National Cancer Institute Toxicity Criteria, Version 2.
A staff nurse reviewed the patient hourly during the first 4 hours and recordings 
were taken, including temperature, heart rate and blood pressure. 4-hourly review 
and recordings were taken during the remaining period. Blood samples were taken 
for detection of HSV (DNA and infectious HSV) and antibody levels at inteiwals 
post-viral injection and postoperatively for at least 4-6 weeks.
The following medications were available in the ward for use in the case of 
medical emergency: lOOmg hydrocortisone for intravenous injection; adrenaline 
(1:1000) for subcutaneous injection and 10 mg chlorpheniramine for intravenous 
injection.
Group C patients were then taken to theatre for surgical resection, 24 hom*s post­
injection, and groups A, B and D patients were given the opportunity to go home 
and return on the day before theatre, depending on clinical and social 
circumstances. All patients were reviewed again prior to theatre, and any new 
symptoms, clinical signs, or changes at the sites of viral injections were noted.
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In theatre, all patients had en bloc resections of their tumours, and some required 
lymph node neck dissections and/or reconstructive surgery. Biopsies were also 
taken at the site of viral injection into the contralateral buccal ’ mucosa 
(approximately 2cm x 1cm).
As soon as the tumour was resected a 5 mm punch biopsy was taken at the site of 
injection, and half snap frozen in liquid nitrogen for PCR and detection of 
infectious HSV, with the other half fixed in formalin for immunohistochemistry 
and in-situ hybridisation. In larger tumours, 2 adjacent biopsies were taken along 
with a biopsy distant from the injection site, to obtain more tissue and aid 
detection of viral spread. Half the buccal mucosa biopsy was also snap fi’ozen, and 
half fixed in formalin. All formalin fixed tissue was sent to the Pathology 
Department, Glasgow Royal Infirmary, along with the tumour resection, for 
sectioning, staging and reporting by Professor MacDonald, Consultant 
Pathologist.
Following discharge, patients were followed up in the multi-disciplinary head and 
neck clinic. Patients were initially seen 1-2 times per month, and then this was 
extended to 3 monthly appointments during the first 12 months. Any patients 
requiring postoperative radiotherapy and/or chemotherapy were treated at the 
Beatson Oncology Centre, Glasgow. All patients will be followed up regularly for 
at least the first 5 years post-treatment.
3.2.4 BLOOD: RED BLOOD CELL AND SERUM EXTRACTION
Blood samples, in their pink-topped potassium EDTA tubes, were centrifuged at 
2000 rpm in a bench-top Beckman-type centrifuge for 5 minutes at room 
temperatm'e. 200pl from the upper serum layer was stored at ~70^C for detection
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of infectious HSV. The remainder of the serum was stored at ~20^C for HSV 
antibody screening and archiving.
The red blood cells were stored at ~20^C in preparation for DNA extraction and 
archiving.
3.2.5 DETECTION OF SERUM HSV-1 IgG AND IgM ANTIBODIES
Detection of human semm IgG and IgM antibodies against HSV-1 was performed 
using an ELISA kit (Virotech). The antibodies formed immune complexes with 
the antigen coated on the micro titre test strips. All experiments, positive and 
negative controls, cut-off controls and patient sera, were performed in duplicate. 
Unbound immunoglobulins were removed by washing processes with PBS. The 
enzyme conjugate attaches to the immune complex, and unbound conjugate was 
removed by washing processes. After adding the substrate solution, 
tetramethylbenzidine, a blue dye was produced by the bound enzyme, peroxidase. 
The colour changed to yellow when the citrate stopping solution was added. The 
colour change was read using an ELISA plate spectrophotometer, set at a 
wavelength o f 450 nm and reference length of 620 nm, to give a measure 
extinction (OD) value.
The OD values of the controls enabled quantification of a semi-quantitative 
determination o f specific IgG and IgM antibodies. Their quantity was expressed in 
Virotech units (VE).
Calculation o fV E  units: VE (positive control) = OD positive control x 10
OD cut-off control
VE (patient serum) ~ OD vatient serum x 10
OD cut-off control
3.2.6 DNA EXTRACTION FROM RED BLOOD CELLS
DNA was extracted from human red blood samples using a Nucleon® genomic 
DNA extraction kit, in a designated laboratory to minimise contamination. 0.5 ml 
samples of red blood cells were prepared and lysed using the appropriate kit 
reagents. Following deproteination, the DNA extraction was performed using 
Nucleon® resin, without chloroform. The DNA was precipitated out using 
isopropanol, and washed with 70% ethanol. Each DNA extract was resuspended 
in 50pl of nuclease free water.
3.2.7 DNA EXTRACTION FROM HUMAN TISSUE
DNA from human tissue biopsies was extracted using the same Nucleon® kit and 
protocol as for red blood cell samples. In addition, prior to cell preparation and 
lysis, the tissue samples were homogenised in eppendorf tubes using an electric 
cordless homogeniser. Also, during cell lysis, the samples were incubated at 37°C 
overnight, rather than for 10 minutes.
3.2.8 HSV POLYMERASE CHAIN REACTION (PCR): BLOOD AND 
TISSUE SAMPLES
All reactions were set up in an ultraviolet cabinet in a laboratory solely used for 
human sample DNA extraction and PCR, to minimise contamination.
DNA extracted from BHK cells was used as controls. HS 13 (ACG ACG AC G 
TCC GAC GGC GA) and HS 14 (GTG CTG G IG  CTG GAG GAC AC) primers 
were used, which detect the UL42 locus of HSV (Puchhammer-Stockl et al 1990), 
and were made up as liiM/pl stocks in sterile, deionised water.
PCR reagents used per reaction were: 1.5pl 10 mM deoxynucleotide mix; 5 pi 
(lOx) Pfx amplification buffer; 0.5 pi Platinum® Pfx DNA polymerase; 1 pi 50
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mM Mg2SÛ4; 1 pi 0.1 nM dilution of HS 13; 1 pi 0.1 nM dilution of HS 14; 1 pi 
DNA template; all made up to 50pl total volume in sterile deionised water.
PCR conditions were 94^C for 2 minutes; 32 cycles x (94^C for 15 seconds, 72°C 
for 1 minute, 72^C for 1 minute); 72 C for 2 minutes followed by a 4°C 
incubation.
After PCR, 20 pi of each reaction was electrophoresed on a 1% agarose gel and 
observed for a 278-bp band indicative of HSV. lOObp and 1Kb DNA markers of 
known concentration were run alongside the DNA samples to enable confirmation 
of the fragment size.
3.2.9 AGAROSE GEL ELECTROPHORESIS
PCR analysis used 100 ml gels of 1% agarose boiled in Ix TBE buffer. Once 
cooled to 75°C, 5pi of ethidium bromide was added and the solution poured onto a 
sealed plate, with a Teflon-coated well-forming comb (12-18 teeth) positioned. 
Once set, the gel was placed in a gel tank containing IxTBE and the samples 
added and electrophoresed at 80-100 V for 45-75 minutes. The gels were 
visualized using a short wave ultraviolet lamp and photographed on Polaroid film.
3.2.10 HSV IMMUNOHISTOCHEMISTRY
Immunohistochemistry for HSV was performed on paraffin sections using a rabbit 
polyclonal antibody to HSV-1 (DAKO), dilution 1:100. Anti-rabbit secondary 
antibody (DAKO) was used at a 1:50 dilution. The regional centre for 
immunohistochemistry at Glasgow Royal infnmary performed the experiments.
3.2.11 HSV IN-SITU  HYBRIDISATION (ISH): TISSUE SAMPLES 
HSV DNA was detected using the Rembrandt® in situ hybridisation kit.
90
5 pm paraffin sections of tissue biopsies were cut in additive-free distilled water at 
55°C. The sections were collected on organosilane coated glass slides and baked 
at 56-60^C in a dry air oven for 2-16 hours.
Experiments were performed with negative and positive control slides, the latter 
being cultured HSV-1 infected human embryonic lung fibroblast cells. Prior to 
ISH the slides were dewaxed in fresh histoclear for 2 x 10 minutes. The slides 
were then placed in 100% ethanol for 5 minutes and air dried for 10 minutes.
A proteolytic treatment solution was prepared by mixing 50pl of the kit pepsin 
digestion reagent to 5ml IM HCl. 400pl of the solution was added to each slide 
and incubated at 37®C for 30 minutes.
Following dehydration of the slides in graded ethanol washes, the hybridisation 
was performed. 20pl of the negative or positive digoxigenin labelled DNA probe 
was added to sections and a coverslip positioned over the section. Incubating the 
slides on a 95°C hotplate for exactly 5 minutes denatured the sections. They were 
then put in a humidified chamber and incubated overnight at 37®C.
The slides were submerged in TBS to remove the coverslips and washed in 
formamide.
For detection and staining, alkaline phosphatase conjugated aDIG was added to 
sections and incubated for 30 minutes at 37°C. Following a TBS wash, NBT/BCIP 
substrate was added to each section and incubated in the dark at 37°C for 15 
minutes. Following a wash in distilled water, the slides were mounted with an 
aqueous mounting medium.
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3.2.12 DETECTION OF INFECTIOUS HSV1716: SERUM AND TISSUE 
SAMPLES
Serum: ETCio medimu was removed from confluent monolayers of BHK21/C13 
cells on 60mm diameter tissue culture dishes. 200pl of serum was added to each 
plate and overlaid immediately with ETMC 10% to avoid toxicity to the cells. 
Tissue: Samples were homogenised in eppendorf tubes using an electric cordless 
homogeniser, and suspended in 1ml of ETCio. Following bath-sonication for 5 
minutes, the tubes were spun in a Beckman-type bench-top centrifuge at 2000 rpm 
for 5 minutes. The supernatant was decanted from each tube and 500pl was added 
to confluent monolayers of BHK21/C13 cells on 60mm diameter tissue culture 
dishes, following removal of the ETCto medium. The dishes were left for 30 
minutes at 37®C before adding 4.5ml of ETMC 10%,
All dishes were incubated at 31°C for 3 days, and observed daily for signs of viral 
infection.
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CHAPTER 4
RESULTS
4.1 CHARACTERISATION OF THE CYTOTOXIC EFFECTS IN  
VITRO OF HSV1716 AND HSV1716 PLUS CISPLATIN AGAINST HEAD 
AND NECK SQUAMOUS CARCINOMA CELLS
4.1.1 INTRODUCTION
HSV1716 is a deletion mutant o f HSV-1, which is selectively replication 
competent. It fails to make the virulence factor ICP34.5 (MacKay et al, 1993). 
HSV1716 does not replicate in teiminally differentiated cells or cause encephalitis 
following intracranial inoculation of animals or humans (MacLean et al, 1991; 
Rampling et al, 2000; Papanastassiou et al, 2002; Harrow et al, 2004). Cytotoxic 
effects of ICP34.5 null mutants of HSV-1 have been seen against a number of 
tumour types including glioblastoma, medulloblastoma, mesothelioma and 
melanoma (Mineta et al, 1995; Lasner et al, 1996; Kucharczuk et al, 1997; 
Randazzo et al, 1997). HSV1716 infection of head and neck squamous cell 
carcinoma cells has not been studied before.
Thi'ee HNSCC cell lines were chosen to work with, UM-SCC-14C, UM-SCC-22A 
and UM-SCC-22B (Grenman et al, 1991, Carey et al, 1983). Professor Guus van 
Dongen, VU University Medical Centre, Amsterdam kindly provided all the cells. 
The characteristics of the cells are shown in Table 9. 22A and 22B, a lymph node 
metastasis from the same patient. It was necessary to use cells that did not require 
the use of feeder cell layers. If virus infected epithelial feeders, any results 
attained would be invalid.
Cisplatin is a platinum based chemotherapy agent, which is commonly used in 
head and neck cancer. It enters the cell by passive diffusion, where it is 
hydrolysed to its active form due to the low chloride concentration inside the cell. 
It binds to proteins and nucleic acids causing DNA damage and cell apoptosis.
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Table 9: HNSCC CELL LINES
(Donor information and specimen site. 22A and 22B cells are from the same 
patient))
UM-SCC-14C 58 FEMALE TINOMO I FLOOR OF MOUTH
UM-SCC-22A 58 FEMALE T2N1M0 II HYPOPHARYNX
UM-SCC-22B 58 FEMALE T2N1M0 II HYPOPHARYNX
Combining cancer therapies can potentially produce additive or synergistic 
effects, along with decreased side effects and overall, a better outcome. The 
potential side effects, including encephalitis, of HSV1716 do not overlap with 
cisplatin. Also, cross-resistance is theoretically unlikely due to the radically 
different mechanisms of action o f viral and chemotherapeutic agents.
HSV1716 has an attractive profile for investigating as a novel head and neck 
cancer therapy, and could potentially be used in combination with conventional 
chemotherapy agents. Initial studies established the pennissivity of HNSCC to 
HSV1716, and the cytotoxic effects of HSV 1716 and cisplatin in isolation. The 
potential for enlianced cytotoxic effects by combining the two agents was then 
investigated.
4.1.2 GROWTH KINETICS OF HSV1716 IN HNSCC CELL LINES
Initial experiments aimed to establish permissivity of HNSCC cell lines to 
HSV1716. Studies have shown that PCNA levels are high in head and neck cancer 
cells and this high level of PCNA expression is associated with advanced disease
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and poor prognosis (Sarac et al, 1998; Liu et al, 2003; Krecicki et al, 1999). This 
gave expectations of HSV1716 being able to replicate in the three cell lines. 
Multicycle replication kinetics of HSV1716 and wild type HSV, strain 17"^ , were 
examined by infecting UM-SCC-14C, UM-SCC-22A and UM-SCC-22B at a low 
multiplicity o f infection (MOI). The cells were infected with the viruses at an 
MOI of 0.1 pfu/cell and the cells/virus harvested at 0, 6, 24, 48 and 72 hours post­
infection. The samples were sonicated and progeny virus titrated in BHK21/C13 
monolayers.
Figure 9 shows the growth kinetics o f HSV 1716 and HSV strain 17"^  in confluent 
UM-SCC-14C, BHK and 3T6 cells. BHK and 3T6 cells were used as controls as 
both are known to be fully permissive for HSV strain 1 7 \ but 3T6 cells are only 
permissive for HSV strain 17"^  and are non-pennissive for HSV1716. The graph 
shows predictable results for the control cells and UM-SCC-14C cells are seen to 
be fully permissive for HSV strain 17'*' and semi-permissive for HSV1716.
Figure 10 shows the growth kinetics o f HSV1716 and HSV wild type, strain 17 \ 
in confluent UM-SCC-22A, BHK and 3T6 cells. The control cells show 
predictable results and UM-SCC-22A cells are seen to be fully permissive for 
HSV strain 17"^  and semi-permissive for HSV1716.
Figure 11 shows the growth kinetics of HSV1716 and HSV strain 17'*' in confluent 
UM-SCC-22B, BHK and 3T6 cells. The control cells show predictable results and 
the UM-SCC-22B cells are seen to be semi-permissive for HSV strain 17’*' and 
HSV1716.
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Figure 9. MULTICYCLE GROWTH KINETICS OF HSV1716 AND HSV 
WILD TYPE, STRAIN 17+, IN UM-SCC-14C, BHK AND 3T6 CELLS
UM-SCC-14C, BHK and 3T6 cells were infected with HSV1716 or HSV-1, strain 
17+, at an MOI of 0.1 pfu/cell. Infected cells were harvested at 0, 6, 24,48 and 
72 hours post-infection and progeny virus titrated on BHK21/C13 cells. Graph 
produced with Microsoft (MS) Excel computer software.
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Figure 10. MULTICYCLE GROWTH KINETICS OF HSV1716 AND HSV 
WILD TYPE, STRAIN 17+, IN UM-SCC-22A, BHK AND 3T6 CELLS
UM-SCC-22A, BHK and 3T6 cells were infected with HSV1716 or HSV-1, strain 
17+, at an MOI of 0.1 pfu/cell. Infected cells were harvested at 0, 6, 24, 48 and 
72 hours post-infection and progeny virus titrated on BHK21/CI3 cells Graph 
produced with MS computer software.
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Figure 11. MULTICYCLE GROWTH KINETICS OF HSV1716 AND HSV 
WILD TYPE, STRAIN 17+, IN UM-SCC-22B, BHK AND 3T6 CELLS
UM-SCC-22B, BHK and 3T6 cells were infected with HSV1716 or HSV-1, strain 
17+, at an MOI of O.I pfu/cell. Infected cells were harvested at 0, 6, 24, 48 and 72 
hours post-infection and progeny virus titrated on BHK21/C13 cells. Graph produced 
with MS Excel computer software.
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Thus all three HNSCC cell lines have been shown similar trends by being permissive 
for replication of HSV1716, but the level of replication is less than that demonstrable 
in fully permissive BHK cells, and more than that demonstrable in confluent non- 
permissive 3T6 cells. The intermediate level of replication is a good result for an 
agent to study in combination therapy experiments. It would be more difficult to look 
for evidence o f enhanced cytotoxicity in combination experiments if  the cells were 
fully permissive for HSV 1716 replication. Potential add on effects of cisplatin would 
be masked.
4.1.3 INTERACTIONS BETWEEN HSV1716 AND CISPLATIN
Before proceeding with cytotoxicity experiments it was essential to make sure that 
there were no toxic interactions between the two agents. Titrations of a stock of 
IHSV1716 were performed. Tliree titrations were performed adding serial dilutions 
of HSV1716 alone to 85% confluent BHK cells on 60mm petri dishes. The virus was 
added iimnediately in one experiment and after incubations for 1 hour at room 
temperature and 1 hour at 37^C in the other two experiments respectively. Tlnee 
further experiments were performed applying the same temporal and temperature 
condition but lOpM cisplatin was added to each virus sample. This was a higher dose 
of cisplatin than would be used in the cytotoxicity experiments. The results of the 
titrations experiments are shown in Table 10. Similar trends are seen in the final titre 
values as all values are to the same power of lO^.and would hardly be detectable on a 
logarithmic scaled graph as in figures 9-11. This indicates that a concentration of 10 
pM cisplatin is not detrimental to HSV1716 infectivity.
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Table 10: HSV1716 titrations with and without lOpM cisplatin
HSV1716 ALONE VIRUS ADDED IMMEDIATELY
HSV1716 ALONE 1 HOUR AT ROOM TEMP. 1.9 X 10'"
HSV1716 ALONE 1H0URAT37^C 2.1 X 10'"
HSV1716 +CISPLATIN VIRUS ADDED IMMEDIATELY 1.9X10'"
HSV1716 +CISPLATIN 1 HOUR AT ROOM TEMP. 1.9 X 10 '"
HSV1716 +CISPLATIN 1 H0URAT37"^C 2.6X10'"
A multicycle growth experiment was repeated to establish any interactions between 
HSV1716 and cisplatin that would affect the growth kinetics of the virus in HNSCC 
cell lines. UM-SCC-14C and BHK cells were infected with HSV1716 at an MOI of 
0.1 pfu/cell. In parallel experiments the same cells were infected with HSV1716 and 
l.OpM cisplatin. This cisplatin concentration would be used in cytotoxicity 
experiments. All cells/virus +/- cisplatin were harvested at 0, 6, 24, 48 and 72 hours 
post infection. The samples were sonicated and progeny virus titrated on 
BHK21/C13 monolayers.
Figure 12 shows the growth kinetics of HSV1716 in confluent UM-SCC-22A and 
BHK cells, with and with out the presence of 1 .OpM cisplatin. The cisplatin does not 
affect the final viral titres and is not detrimental to HSV1716 infectivity.
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Figure 12. MULTICYCLE GROWTH KINETICS OF HSV1716 IN UM-SCC- 
14C AND BHK CELLS, WITH AND WITHOUT THE PRESENCE OF 
CISPLATIN
UM-SCC-14C and BHK cells were infected with HSV1716 at a MOI of 0.1 pfu/cell, 
with and without the presence of 1 .OpM cisplatin. Infected cells were harvested at 0, 
6, 24, 48 and 72 hours post-infection and progeny virus titrated on BHK2I/C13 cells. 
Graph produced with MS Excel computer software.
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4.1.4 HSV1716 CYTOTOXICITY IN HNSCC CELL LINES
HSV1716 cytotoxicity in HNSCC cell lines was studied using a colorimetric MTS 
tétrazolium assay (Promega). The assay measures dehydi'ogenase enzyme activity 
found in metabolically active cells. The intensity of the colour change produced by 
the bioreduction of tétrazolium to formazan is proportional to the number of living 
cells. Before proceeding with cytotoxicity experiments it was necessary to confirm a 
linear relationship between viable cell numbers and colorimetric MTS optical density 
readings, taken at 480nm. A standard curve was produced using UM-SCC-22B cells. 
Cells were seeded in a 96 well plate at densities between 375 cells per well and 
12,000 cells per well in 100 pi volumes of appropriate media. Each cell density was 
performed in six replicates to reduce errors when averaging the results. The plate was 
incubated at 37^C for 20 hours. All wells were aspirated dry and replaced with 100 pi 
of fresh media. Six additional wells were set up with 100 pi of fresh media. 20 pi of 
MTS mixture was added to each well and the plates incubated for 2%. hours. Optical 
readings were taken and the value for each cell density taken as an average over six 
wells. The readings fi*om the wells containing media alone were also averaged. 
Corrected readings were then calculated by subtracting the averaged media reading 
fi'om the averaged reading for each cell density. The results were plotted on a graph 
(Figure 13).
The graph shows a linear relationship and an value of 0.9864. This result has 
significance for cytotoxicity experiments when plotting MTS absorbance readings 
against different concentrations of a cytotoxic agent. A fifty per cent reduction in 
MTS absorbance reading indicates a 50% reduction in viable cells.
An in vitro model was then designed to study the cytotoxic effects of HSVI716 on 
HNSCC cell lines. Many problems were encountered. All tlnee cell lines were found
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Figure 13: Standard curve o f UM -SCC-22B cell absorbance at 480nm  versus 
cell concentration. The value is the fraction o f the variance in the data that is 
explained by regression. At 0.9864 the regression is approaching unity and so the 
absorbance is directly proportional to the number o f cells. Graph produce with MS 
Excel computer software.
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to be difficult to work with and at times their behaviour was unpredictable. They 
were prone to going into growth arrest at any time and this did not correlate with the 
number o f times they had been passaged.
A cytotoxicity model was needed to produce dose response curves to determine IC50 
values, the concentration o f cytotoxic agent required to inhibit the cell number by 
50%. It was first necessary to determine optimal initial cell seeding densities. Cells 
were to be exposed to different MOIs of HSV1716 and the results compared to cells 
exposed only to media. Absorbance readings were to be taken 72 hours after 
exposure to the cytotoxic agent, which is standard for this type of experiment. Ideally 
the cells should grow exponentially throughout the experiment and the control cells, 
exposed only to media, should reach 90-100% confluence at 72 hours.
Optimal seeding densities were found to be 4000 cells per well for UM-SCC-14C 
and 6000 cells per well for UM-SCC-22Aand UM-SCC-22B. It was also found to be 
important to seed cells taken from 70-80% confluent T-175 flasks. In this state the 
cells were already growing exponentially and at a full spectrum of stages in the cell 
cycle. If cells were seeded from fully confluent flasks, their growth in 96 well plates 
was unpredictable and initially very slow.
Having established optimal cell seeding densities, experiments were carried out to 
determine the 1C50 of HSV1716 for each cell line. After the seeded cells were 
incubated at 37°C overnight the media was removed and serial concentrations of 
HSV1716 were added in 100 pi volumes. Each viral concentration was performed in 
six replicates to reduce errors. A control lane of six wells was prepared, with cells 
exposed only to media. After 72 hours incubation at 37°C, all wells were aspirated 
dry and 100 pi o f fresh media added to avoid errors when taking optical density 
readings. A frirther control lane was prepared with six wells, each containing 100 pi
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of fresh media. 20 pi of MTS reagent was added to each well and the plates 
incubated for 214 hours. Optical readings were taken and the value for each viral 
MOI and control lanes was calculated as an average over six wells. The experiments 
were repeated many times until satisfactory consistency in the results was achieved. 
Particular problems that had to be addressed were the different rates of cell growth 
and cross-contamination while pipetting into wells and the accuracies o f the cell 
counting and cell seeding. Wlien seeding 4000 cells into a well a realistic error of 
1000 cells is a notable 25% error. Dose response curves were produced for each cell 
line and IC50 values calculated accordingly. All experiments were repeated until 
consistency was achieved, HSV1716 has not been used before with HNSCC so there 
was no published data with which to compare IC50 values.
4.1.5 CALCULATION OF IC50 VALUE
Adjusted absorbance values were calculated by subtracting the average absorbance 
value from wells containing media alone. These adjusted absorbance values were 
plotted against viral MOI (Figure 14).
Dose response curves for UM-SCC-14C, UM-SCC-22A and UM-SCC-22B with 
HSV1716 are shown in Figures 15, 16 and 17. The HSV1716 IC50 values for the 
three HNSCC cell lines are shown in Table 11.
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Figure 14: METHOD OF DETERMINING IC50 USING A DOSE RESPONSE
CURVE. The IC50 is the x-axis intercept of the curve at the point determined by a 
50% reduction in absorbance and therefore cell viability.
HNSCC CELL LINE DOSE RESPONSE CURVES WITH H SV !716
Figure 15: UM-SCC-14C DOSE RESPONSE CURVE WITH HSV1716
UM-SCC-14C cells were infected with serial concentrations of HSV1716. Each viral 
concentration was performed in 6 replicates to reduce errors. Optical readings were 
taken at 72 hours. Graph produced with MS Excel computer software.
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Figure 16: UM-SCC-22A DOSE RESPONSE CURVE WITH HSV1716
UM-SCC-22A cells were infected with serial concentrations of HSV1716. Each viral 
concentration was performed in 6 replicates to reduce errors. Optical readings were 
taken at 72 hours. Graph produced with MS Excel computer software.
DOSE RESPONSE
Figure 17: UM-SCC-22B DOSE RESPONSE CURVE WITH HSV1716
UM-SCC-22B cells were infected with serial concentrations of HSV1716. Each viral 
concentration was performed in 6 replicates to reduce errors. Optical readings were 
taken at 72 hours. Graph produced with MS Excel computer software.
DOSE RESPONSE
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Table 11: HSV1716 IC50 VALUES FOR HNSCC CELL LINES (72 HOURS)
UM-SCC-14C UM-SCC-22A UM-SCC-22B
0.55 +/- 0.12 0.15 +/- 0.039 0.35 +/- 0.074
4.1.6 CISPLATIN CYTOTOXICITY IN HNSCC CELL LINES
The same MTS assay in vitro model was use to study the cytotoxic effects of 
cisplatin alone on HNSCC cell lines. The cells were seeded in 96 well plates and 
after 24 hours incubation at 37°C the cells were exposed to a range of concentrations 
of cisplatin between 0.5 pM and 5 pM. Each cisplatin concentration was performed 
in six replicates to reduce errors. The same protocol was adhered to as for HSV1716. 
Optical readings were taken and the value for each cisplatin concentration and 
control lanes calculated as an average over six wells. Dose response curves were 
produced for each cell line and IC50 values calculated accordingly. Dose response 
curves for cisplatin with UM-SCC-14C, UM-SCC-22A and UM-SCC-22B are 
shown in Figures 18, 19 and 20. All experiments were repeated until consistency was 
achieved. The cisplatin IC50 values for the tlu*ee HNSCC cell lines are shown in 
Table 12. Previously published cisplatin IC50 data is also included (Welters et al, 
1997)
The IC50 values are consistently higher in comparison to the results of Welters et al, 
however the trend and the enor margins are similar. The differences can be 
explained by the use o f different culture media ingredients, and more importantly the 
perfonnance of a different cytotoxicity experiment. They used a semi-automated 
proliferation assay with sulforhodamine B and the cells were incubated for 72 hours 
at 37^C prior to cisplatin exposure.
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Figure 18: UM-SCC-14C DOSE RESPONSE CURVE WITH CISPLATIN
UM-SCC-14C cells were infected with serial concentrations of cisplatin. Each 
cisplatin concentration was performed in 6 replicates to reduce errors. Optical 
readings were taken at 72 hours. Graph produced with MS Excel computer software.
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Figure 19: UM-SCC-22A DOSE RESPONSE CURVE WITH CISPLATIN
UM-SCC-22A cells were infected with serial concentrations of cisplatin. Each 
cisplatin concentration was performed in 6 replicates to reduce errors. Optical 
readings were taken at 72 hours. Graph produced with MS Excel computer software.
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Figure 20: UM-SCC-22B DOSE RESPONSE CURVE WITH CISPLATIN
UM-SCC-14C cells were infected with serial concentrations of cisplatin. Each 
cisplatin concentration was performed in 6 replicates to reduce errors. Optical 
readings were taken at 72 hours. Graph produced with MS Excel computer software.
DOSE 
RESPONSE
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Table 12: CISPLATIN IC50 VALUES FOR HNSCC CELL LINES 
(72 HOURS)
UM-SCC-14C UM-SCC-22A UM-SCC-22B
3.8 +/- 0.8 2.0 +/- 0.5 2.4 +/- 0.4
2.7 +/- 0.7 1.3 +/- 0.3 1.2 +/- 0.3
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4.1.7 HSV1716 CYTOTOXICITY IN COMBINATION WITH CISPLATIN
IN HNSCC CELL LINES
Having established the cytotoxicity profiles of HSV1716 and cisplatin in isolation, it 
was then possible to perform combination experiments. By combining the agents at 
doses less than their respective IC50 values it would be possible to look for signs of 
enhanced cytotoxic effects.
MTS assay experiments were performed with the same protocol and cell seeding
densities as with each agent in isolation. 0.5 pM, 1.0 pM and 1.5 pM doses of
cisplatin were each combined with doses of HSV 1716 at MOI 0.01 pfu/cell, MOI
0.05 pfu/cell and MOI 0.1 pfu/cell. All experiments were carried out over 72 hours to
produce dose response curves and corresponding IC50 values. Figure 21 shows an
example of how the IC50 was calculated for each combination.
Figure 21: UM-SCC-22A: HSV1716 (MOI 0.01)+CISPLATIN DOSE
RESPONSE CURVE. UM-SCC-22A cells were infected with HSV1716 (MOI 
0.01) and serial concentrations of cisplatin. Each combination of virus and cisplatin 
was performed in 6 replicates to reduce errors. Optical readings were taken at 72 
hours. Graph produced with MS Excel computer software
ISPLATIN + HSV 1716 (MOI 0.01
CISPLATIN + HSV 
1716 (MOI 0.01)
ISPLATIN c o n c e n t r a t i o n !  (M**) 'L-Ç* , \  K M Ë ‘Éi
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HSV1716 MOI 0.01 was combined with different doses of cisplatin and the solid 
blue line shows the effects on cell viability after 72 hours. The IC50 was calculated 
for this combination of doses and is shown by the red line intersecting the x-axis at 
1.2 pM. Therefore a dose of HSV1716 at 0.01 MOI requires 1.2 pM of cisplatin to 
kill 50% of the cells. Figure 22 compares the % cell viability at 72 hours of cells 
exposed to 1.2 pM of cisplatin alone, HSV 1716 alone at 0.01 MOI and a 
combination of the agents at the same doses.
Figure 22: UM-SCC-22A: % cell viability at 72 hours following exposure to 
HSV1716 (0.01 MOI) and cisplatin (1.2 pM) alone and in combination. Optical 
readings were taken at 72 hours.
UM-SCC-22A:% cell viability at 72 hours
10090
8070
605040
3020100
Cisplatin alone 
(1.2 pM)
HSV1716 alone Cisplatin (1.2 pM) 
(0.01 MOI) and HSV 1716 
(0.01 MOI) 
combined
IC50 values were calculated for each dose combination with each cell line and the 
results are shown in Table 13.
Figure 22 and Table 13 indicate signs of enhanced cytotoxicity when HSV1716 and 
cisplatin are added in combination. It is not possible to qualify this and also
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Table 13: COMBINATION IC50 VALUES (72 HOURS)
UM-SCC-14C 0.01 3.2
UM-SCC-14C 0.05 2.5
UM-SCC-14C 0.1 2.3
UM-SCC-22A 0.01 1.2
UM-SCC-22A 0.05 0.9
UM-SCC-22A 0.1 0.6
UM-SCC-22B 0.01 1.6
UM-SCC-22B 0.05 1.2
UM-SCC-22B 0.1 0.7
distinguish between antagonism, additivity or synergy without further analysis of the 
data. It is not possible to simply add the effects of the agents used in isolation. This is 
only possible if two agents follow closely to first-order kinetics, which would 
produce linear dose response curves. Synergy, additivity and antagonism would be 
deemed to be present if  the effect of the combined agents were, respectively, more 
than, equal to or less than the sum of the effects of the constituents.
The combined cytotoxic effects of HSV I716 and cisplatin, which do not follow first- 
order kinetics, can be evaluated using an isobologram analysis (Kano et al, 1988, 
Kano et al, 1992). This method forms 3 isoeffect curves (Mode I, Ila and Jib) on an 
isobologram graph and the outermost boundaries o f the 3 lines forms an envelope of 
additivity (Figure 23). The area to the left of the envelope is the zone of synergy, and 
the area to the right is the zone of antagonism. The combination IC50 doses from
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Table 11 can be plotted on the graph and conclusions made regarding antagonism, 
additivity and synergy between the two agents.
\ \  I \ ( . ( ) M s \ l
DOSE OF B
DOSE OF A
Figure 23: Isobologram graph. An envelope of additivity is constructed from 
the dose response curves o f 2 agents (A and B). Combination IC50 data points 
can fall into 3 areas with corresponding classification of the 2 agents 
interactions as antagonistic, additive or synergistic.
The 3 isoeffect curves take into account that the combined effect of the two agents 
could be completely independent (heteroadditive), dependent (isoadditive) or 
intermediate. The Mode I, Mode Ila and Mode Ilb curves were produced on the 
isobologram graphs as follows (Kano et al, 1992).
Mode I Curve: This curve is formed on the assumption that the effects of 
cisplatin and HSV1716 are completely independent of each other. When a dose of 
HSV1716 is chosen there remains an increment in effect to be produced by cisplatin 
to obtain 50% cell growth inhibition. If the 2 agents were to act independently, the
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addition is performed by taking the increment in doses, starting from zero, that give
log survivals which add up to IC50.
Figures 24 and 25 are the dose response curves for UM-SCC-14C with HSV1716 
and cisplatin in isolation. The gridlines on the graphs have been excluded. A dose of 
HSV1716 (VI) was chosen and the fraction affected (inliibited) was F. To obtain 
50% cell growth inliibition, an increment in effect, X, remained to be produced by 
cisplatin (Figine 24). Therefore F+X=50. The addition was performed by taking the 
increment in doses, starting from zero, which produced log survivals that added up to 
IC50 (heteroaddition) (Figure 25). X is marked on Figure 24 and the dose of cisplatin 
required is marked as C l. Therefore plotting different doses o f HSV1716, V I, with 
the corresponding dose of cisplatin, C l, produces the Mode I cuiwe. For convenience 
the IC50 for each agent in isolation is plotted as 1.0 on the isobologram, therefore no 
units are required.
Mode Ila curve: This curve is formed on the assumption that there is some 
interaction between the effects of cisplatin and HSV1716. When a dose of HS V I716, 
VI, was chosen, an increment in effect, X, remained to be produced by cisplatin. The 
addition was performed by taking the increment in doses, starting not from zero but 
from the point on the dose response curve of cisplatin where the effect of HSVI716 
had ended (F), that produced log survivals that added up to IC50 (iso-addition). The 
dose of cisplatin required is marked as C2 (Figure 25). Therefore plotting different 
doses of HSVI716, V I, with the corresponding dose of cisplatin, C2, produces the 
Mode Ila curve.
Mode lib  curve: This curve is fonned on the assumption that there is some 
interaction between the effects of cisplatin and HSV1716. Wlien a dose of cisplatin. 
C l, was chosen, an increment in effect, F, remained to be produced by HSV1716.
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The addition was performed by taking the increment in doses, starting not from zero 
but from the point on the dose response curve of HSV1716 where the effect of 
cisplatin had ended (X), that produced log suiwivals that added up to IC50 (iso­
addition). The dose of HSV1716 required is marked as V2 (Figure 24). Therefore 
plotting different doses o f cisplatin, C l, with the corresponding dose of HSVI716, 
V2, produces the Mode lib curve.
In summary the Combination doses VI and Cl (Mode I), VI and C2 (Mode Ila), and 
V2 and Cl (Mode lib) will each produce 50% cell inhibition.
Representative isobolograms produced from the dose response curves of UM-SCC- 
14C, UM-SCC-22A and UM-SCC-22B with HSV1716 and cisplatin are shown in 
Figures 26, 27 and 28. The envelope of additivity, formed by the outer margins of the 
tliree isoeffect curves, is marked on each graph. Combination IC50 data from Table 
13 have been plotted. All combination plots fall within the envelopes of additivity. It 
is possible to conclude there is additivity when HSV1716 is combined with cisplatin 
in all three HNSCC cell lines. Ergo the effect produced is the sum of the effect of 
either agent alone.
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Figure 24: UM-SCC-14C DOSE RESPONSE CURVE WITH HSV1716
VI is the chosen dose of HSV1716 used to produce the Mode I curve and Mode Ila 
curve. V2 is the dose of HSV1716 used to produce the Mode lib curve.
F is the level of cell inhibition resulting from VI. X is the level of cell inhibition to 
increase F to 50% (F+X=50).
O 40
0.1 '  1 
HSV 1716 MCI
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Figure 25: UM-SCC-14C DOSE RESPONSE CURVE WITH CISPLATIN
C 1 is the dose of cisplatin used to produce the Mode I curve. C2 is the dose of 
cisplatin used to produce the Mode Ila curve.
X is the level of cell inhibition resulting from C l. F is the level of cell inhibition to 
increase X to 50% (F+X=50).
» 1 2 3 “4 5 6
CISPLATIN CONCENTRATION (pM)
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Figure 26: IC50 ISOBOLOGRAM: UM-SCC-14C WITH HSV1716 AND
CISPLATIN
The outermost boundaries of the 3 isoeffect curves form an envelope of additivity. 
IC50 combination data are plotted and fall within the envelope of additivity. For 
convenience the IC50 for each agent in isolation is plotted as 1.0 on the isobologram, 
therefore no units are required.
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Figure 27: IC50 ISOBOLOGRAM: UM-SCC-22A WITH HSV1716 AND
CISPLATIN
The outermost boundaries of the 3 isoeffect curves form an envelope of additivity. 
IC50 combination data are plotted and fall within the envelope of additivity. For 
convenience the IC50 for each agent in isolation is plotted as 1.0 on the isobologram, 
therefore no units are required.
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Figure 28: IC50 ISOBOLOGRAM: UM-SCC-22B WITH HSV1716 AND
CISPLATIN
The outermost boundaries of the 3 isoeffect curves form an envelope of additivity. 
IC50 combination data are plotted and fall within the envelope of additivity. For 
convenience the IC50 for each agent in isolation is plotted as 1.0 on the isobologram, 
therefore no units are required.
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In summary, we have performed the first studies of the cytotoxic effects of HSV1716 
against PINSCC. Three HNSCC cell lines were used. The growth kinetics of 
HSV1716 in HNSCC cell lines were studied, and each cell line was found to be 
permissive for replication of HSV1716. HSV1716 was found to be cytotoxic to 
HNSCC, and dose response curves were produced for each cell line. IC50 values 
were calculated for each cell line. Cisplatin was found not to be toxic to HSV1716. 
Cisplatin cytotoxicity studies produced IC50 values showing trends and error 
margins comparable to existing published results. Cisplatin was not found to be toxic 
to HSV1716, making them suitable agents for combination cytotoxicity studies. The 
cytotoxic effects of HSV1716 and cisplatin do not follow first order kinetics and so 
isobologi'am analyses of the data from combination studies were perfonned. 
Additivity was observed when HSV1716 was combined with cisplatin in all tlrree 
HNSCC cell lines. Having shown HSV1716 alone and combined with cisplatin to be 
efficacious in HNSCC, we were able to proceed with a phase I toxicity clinical trial.
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4.2 PHASE I STUDY OF PREOPERATIVE INTRATUMOURAL 
INJECTION OF HSV1716 IN ORAL SQUAMOUS CELL CARCINOMA
4.2.1 PATIENT CHARACTERISTICS
A full target population of 20 patients was recruited. The baseline characteristics of 
the patients treated are shown in Table 14. 15 patients were male and 5 were female. 
The mean age was 61 years, and all patients had a Karnofsky performance score 
equal to or above 70%. All patients had a positive history of heavy smoking. 2 
patients had a previous history of HNSCC. One of these presented with a 
metachronous primary malignancy and the other with recunent disease. 15 patients 
presented with advanced stage III or IV disease. 18 patients were HSV-1 seropositive 
at presentation, and 2 were seronegative. Table 15 show the treatment programme for 
each patient. The screening immunology blood tests from each patient are shown in 
Table 16, along with the TNM stage of each tumour. Patients B5, C3 and D4 were all 
notably immunosuppressed. Each of these patients presented with advanced stage III 
and IV disease, with pT4N0, pTSNO and pT3N2 tumours respectively.
4.2.2 TOXICITY AND SAFETY
Having met the eligibility criteria, all patients were allotted to one of four groups. 
Following fully informed consent they received an intratumoural and normal buccal 
mucosal injections of HSV1716, according to the trial protocol (Table 8). All 20 
patients were assessed for signs of toxicity using the National Cancer Institute 
Toxicity Criteria, Version 2.
Preoperative intratumoural injection of HSV1716 was tolerated well in all 20 
patients. All tumours were accessible for viral injection on the ward under local 
anaesthetic spray (lignocaine). Some common sites for oral squamous cell carcinoma 
are shown in Figures 29 a, b, c. The most difficult site to access was the
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AGE (YEARS) MEDIAN
RANGE
61
44-75
SEX MALE
FEMALE
15
5
KARNOFSKY 
PERFORMANCE STATUS 90%
80%
70%
13
6
1
HISTORY OF SMOKING POSITIVE
NEGATIVE
20
0
HISTORY OF 
PREVOIUS HNSCC POSITIVE
NEGATIVE
2
18
TUMOUR STAGING pTl
pT2
pT3
pT4
2
10
3
5
NECK STAGING pNO
pNl
pN2
pN3
PRE-INJECTION 
IMMUNE STATUS HSV SEROPOSITIVE 18 
HSV SERONEGATIVE 2
Table 14: Baseline patient characteristics
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a. Floor of mouth
b. Lateral border o f tongue
c. Buccal mucosa
Figure 29 a, b, c: Examples o f common sites for oral squamous cell carcinoma. 
All sites were easily accessible for preoperative intratumoural injection.
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posterolateral tongue region, extending into the retromolar trigone. Some of these 
patients had trismus, due to tumour invasion and fixation, which made access more 
difficult. With the aids of a good light source and adequate tongue retraction, no 
significant problems were encountered. The lignocaine spray 
gave adequate local anaesthesia. 14 patients experienced discomfbit during viral 
injection, but this settled in less than 5 minutes, and was no worse than the 
discomfoit of venesection. The other 6 patients did not complain of any discomfort at 
all.
All patients remained stable during the 24 hour period o f observation post injection. 
There was no change in the baseline obseiwations for all patients. In particular there 
were no pyi'exias, tachycardias or fluctuations in blood pressure. No patients 
developed any symptoms or signs of toxicity. All patients were examined 24 hours 
post injection. There was no notable change in the tumour or tattooed nonnal buccal 
mucosa at this time point in all patients. In particular there were no signs of change 
in the appearance of the tumour and no new inflammation or ulceration.
All patients progressed to tumour resection according to the trial protocol. 18 patients 
required a free flap reconstruction following tumour resection. 2 patients had 
mucosal transposition flaps. Figures 30-33 show the progression of a patient with a 
recurrent T4 fungating oral SCC, from presentation to tumour resection and 
mandibulai* reconstmction. 11 patients received postoperative radiotherapy, and this 
was declined in 1 patient. 3 patients received postoperative adjuvant 
chemoradiotherapy. No patients developed any symptoms or signs of potential 
HSV1716 related toxicity in the interval between initial injection and resection, or 
during the post resection period. All patients were reviewed regularly during the first
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Figure 30: Fungating T4 oral cavity squamous cell carcinoma
TONGUE
Figure 31: Titanium plate bridging the defect following tumour resection and 
segmental mandibulectomy
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SKIN PADDLE
ILIAC BONE
Figure 32: Osseo-myo-cutaneous DCIA flap used for mandibular reconstruction
Figure 33: Post reconstruction and closure
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8 weeks, and all patients with HNSCC are routinely followed up regularly for 5 years 
following the completion of treatment.
3 patients are known to have died following treatment. 1 patient died due to 
comorbitiy with cardiorespiratory disease. 1 patient died due to disease progression 
and another due to the development and progression of a second primary pulmonary 
malignancy.
4.2.3 HUMORAL IMMUNE RESPONSE
All patients had blood serum samples collected prior to virus injection, and at 
intervals up to 6 weeks post injection. Using the ELISA spectrophotometer, with 
control samples, 18 of the 20 patients treated with HSV1716 had pre-existing 
neutralising antibodies to HSV-1. None of these had any changes in their IgM or IgG 
levels post-injection. The 2 patients who were seronegative for HSV-1 pre-injection 
both seroconverted at 4 weeks and 5 weeks post-injection respectively, indicating an 
immune response.
4.2.4 BLOOD AND TISSUE ANALYSES FOR HSV1716 
A) PCR FOR HSV DNA
DNA was isolated from all blood plasma samples collected and PCR analysis was 
carried out using primers, HS13 and HS14, specific for the UL42 locus of HSV-1 
(Puchliammer-Stock! et al 1990). 7 blood samples showed evidence of HSV DNA as 
shown in Table 17. The blood samples were taken between 24 hours and 3 weeks 
post HSV1716 injection. All the samples were from patients who had received the 
lower dose of 10  ^pfu o f HSV1716.
A typical positive PCR reaction for HSV is shown in Figure 34. Samples C, D, E and 
F show a positive 278 base pair band for HSV.
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Resected tumour was also analysed for HSV DNA, which was detected at the 
injection site in 2 patients. Both these patients were injected with the higher dose of 
5x10^ pfu of HSVI716, one at 24 hours pre-resection and the other at 72 hours pre­
resection. In the latter patient, HSV DNA was detected at a distal site, furthest from 
the injection site. The tumour is shown in Figure 29 c. Both patients also had HSV 
DNA detected in the normal buccal mucosa. One other patient had HSV DNA 
detected in the normal buccal mucosa specimen, having been injected with 10  ^pfu of 
HSV1716. No tissue samples were positive for HSV DNA in the group injected 2 
weeks pre-resection.
PATIENT SAMPLE
A1 24 HOURS POST INJECTION
A2 3 WEEKS POST INJECTION
A3 1 WEEK POST INJECTION
A4 1 WEEKS POST INJECTION
A4 3 WEEKS POST INJECTION
A5 24 HOURS POST INJECTION
AS 1 WEEK POST INJECTION
Table 17. Positive blood samples for HSV DNA, analysed by PCR.
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SAMPLES
HSV POSITIVE 
BAND 
278bp
d/ü UO w eu Z
(/5iz.8<
§
Figure 34. HSV analysis o f blood DNA by PCR
Samples: A
B
C
D
E
F
Patient A l 3 weeks post injection 
Patient A2 1 week post injection 
Patient A3 1 week post injection 
Patient A4 I week post injection 
Patient A4 3 week post injection 
Patient AS I week post injection
1 3 4
B) H&E EXAMINATION AND IMMUNOHISTOCHEMISTRY FOR HSV 
ANTIGEN
Tumour specimens were processed in the pathology department at Glasgow Royal 
infirmary. The specimens were either fixed in formalin immediately following 
resection, or larger specimens were pinned out, labelled and sent fresh to enable 
better gross examination by the pathologist. The specimens were then processed and 
infiltrated with paraffin, as an embedding agent. Planes for sectioning were then 
chosen to produce slides for H&E examination, immunohistochemistry and in-situ 
hybridisation. 5pm sections were cut using a microtome. Figure 35 demonstrates 
perpendicular planes through a tumour and injection site. In larger tumours, planes
Tumour Normal
tissue
Plane for 
sectioning Plane for sectioning
Figure 35: Schematic diagram demonstrating perpendicular planes for 
sectioning through a tumour and injection site, marked ^
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were also chosen through sections of tumour distal to the injection site. All tissue 
processing was performed by experienced teclmicians to the high standards required 
for histopathology reporting. All planes for sectioning of tumour and normal buccal 
mucosa were chosen by Mr. Alastair Mace and Professor MacDonald, Consultant 
Head and Neck Pathologist, who both analysed the final H&E, 
immunohistochemistry slides and in-situ hybridisation slides.
H&E slides o f all tumour sections were analysed and no unexpected inflammation or 
necrosis was noted in any sections. Histology in Figures 36a and 36b confirms SCC 
arising fi'om severely dysplastic surface epithelium. The tumour is moderately well 
differentiated with a cohesive invasive front. There is no perineural or vascular 
invasion.
A consistent finding in the injected normal buccal mucosa sections was inflammatory 
lymphocyte infiltrations, and there was no evidence of necrosis. Figure 37 shows an 
H&E section from normal buccal mucosa injected with HSV1716. Histology 
confirms lightly keratinised epithelium with no dysplasia. Mild non specific 
inflammatory changes are present in the lamina propria.
Tumour tissue and normal buccal mucosa sections were analysed by 
immunohistochemistry using a polyclonal antibody to HSV-1 (DAKO). All 
immunohistochemistry was performed in the West of Scotland Regional Referral 
Unit at Glasgow Royal Infirmary. HSV specific antigen was not detected by the 
antibody in all tumour sections and normal buccal mucosa sections (Figure 38a). The 
positive and negative control slides stained appropriately each time (Figure 38b).
C) /VN/rUHYBRIDISATION FOR HSV ANTIGEN
Tumour tissue and normal buccal mucosa specimens were analysed by in situ 
hybridisation using a digoxigenin labelled HSV DNA probe. All 5pm sections of
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buccal mucosa and tumour were analysed at the injection sites. Positive staining of 
HSV DNA was not detected in tumour tissue or normal buccal mucosa (Figure 39a). 
The positive and negative control slides stained appropriately each time (Figure 39b).
D) DETECTION OF INFECTIOUS HSV1716
Tissue samples of normal buccal mucosa and biopsies from the injection sites and 
distal sites in larger tumours were homogenised and processed to allow detection of 
infectious HSV1716. Blood sera from every blood sample taken from all patient 
samples were also processed to allow detection of infectious HSV1716. No 
infectious virus was recovered from all blood samples and tissue biopsies.
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CHAPTER 5
DISCUSSION
5.1 RATIONALE
HSV1716 has been characterised as a selectively replication competent vims and a 
potential novel cancer therapy. It has been shown to induce tumour regression in 
models of a number of tumour types. Improved survival was seen following 
intratumoural injection of medulloblastoma tmnours in a murine model (Lasner et af 
1996). Significant tumom- regression and improved survival was seen following 
HSV1716 intiatumouial injection of melanoma tumour deposits grown in the brains 
of immunocompetent C57B mice (Randazzo et al, 1995). Similar findings were seen 
when inti'acerebral deposits of human embryonal carcinoma cells were injected with 
HSV1716 (Kesari et al, 1995). Effective oncolysis of malignant mesothelioma, with 
tumour regression and improved suivival, was seen when intmperitoneal deposits 
were injected with HSV1716 (Kucharczuk et al, 1997). A murine model involving 
subcutaneous human melanoma was also successful in showing selective replication 
and efficient oncolysis (Randazzo et al, 1997). Immunohistochemistry confirmed the 
viral replication to be restricted to the tumour cells.
In a clinical setting, a safety profile was initially established in a phase I trial 
involving the intratumoural injection of nine immunocompromised patients with 
glioblastoma, in doses up to lO^pfu (Rampling et al, 2000). There was no evidence of 
toxicity, hnmunoliistochemical analysis showed no significant immunoreactivity of 
tumour cells or adjacent brain tissue for HSV-1 using monoclonal antibodies. There 
was no evidence of HSV1716 or wild type genomes by PCR. Tissue cultures were 
negative. This trial was followed by a proof of principle study (Papanastassiou et al, 
2002). Twelve patients with glioma tumours had their intiatumouial injections four to
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nine days post inoculation with HSV1716 at a dose of 10  ^ pfu. Again there was no 
toxicity and in 2 patients infectious HSV1716 was recovered from the injection site at 
titres in excess of the input dose. The same two patients were seronegative for HSV-1 
pre-injection. They both seroconverted and initial changes in specific IgG were 
detected at 19-21 days post-injection. It was only in these patients that 
immunohistochemistry analysis of tumour tissue for HSV antigen was positive from 
two patients. HSV DNA was detected by PCR at the sites of inoculation in 10 
patients and at distal tumour sites in four. A tumour biopsy taken at post mortem from 
one of the patients, 251 days post-injection, was PCR positive for HSV DNA. One 
further phase I study was conducted involving patients with high-grade glioma 
(Harrow et al, 2004). Twelve patients received injections of HSV1716, at a dose of 
10  ^ pfu into the brain adjacent to excised tumour. There was no toxicity and tlnee 
patients notably survived significantly longer than expected fr'om a disease with a 
median survival of approximately nine months.
A phase I tiial involving melanoma patients had also been conducted (MacKie et al, 
2001). Five patients received intratumoural injections of HSV1716 into subcutaneous 
nodules of metastatic melanoma. There was no toxicity. In one patient, flattening of 
previously palpable tumour nodules was seen 21 days after two direct injections of 
HSV1716. In all tliree patients who received two or more injections there was 
microscopic evidence of tmnom* necrosis. Immunohistochemistry analysis showed 
evidence of viral replication within the limits of the tumour' mass. There was no 
antigen staining in the adjacent nomial connective tissue and the basal layer of the
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epidermis. This latter result suggested that the normal melanocytes were antigen-free.
There was no evidence of infectious virus in any of the samples.
The objective of this thesis was to demonstrate potential and safety of HSVI716 as a 
head and neck cancer therapy. HSV1716 has not been previously studied in HNSCC.
We aimed to determine whether HSV1716 would replicate in and kill HNSCC cell ;
lines. Also to determine if the cytotoxic effects in vitro were enhanced when |
combined with the conventional chemotherapeutic agent cisplatin. In a clinical setting 
we aimed to establish a safety profile for HSV1716 in HNSCC.
In HNSCC, there is a great need for novel therapies, in particular to treat locoregional 
recurrent disease. Current therapies for this disease, including re-iiTadiation and 
chemotherapy, have poor response rates and short progression free intervals. The 
disease and these treatments engender significant morbidity, including dysartlnia, 
dysphagia and pain. A locoregional therapy for this disease, such as intratumoural 
injection of HSVI716, would be an attractive treatment option. Combining therapies 
has the potential for enlianced efficacy, and reduced dose requirements and adverse 
reactions of conventional chemotherapy. As the effects of HSV1716 on HNSCC have 
not been studied before, we needed to establish if these cells were pennissive for 
replication of the virus. We were then able to determine if HSV1716 was cytotoxic to 
HNSCC, and whether any cytotoxicity is entranced when combined with the 
conventional chemotherapy agent cisplatin in vitro. For this therapy to be useful in 
head and neck cancer it was necessary to investigate whether direct intratumoui'al 
injection of HSV1716 is tolerated well and is safe. We conducted a Phase I study 
involving 20 patients with oral squamous cell carcinoma to evaluate this.
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5.2 LABORATORY STUDIES: HNSCC AND HSV1716
In vitro experiments using other replicating herpes simplex viruses, in head and neck 
cancer, have already been reported. 0207 is a replication competent oncolytic virus 
and laboratory studies have demonstrated cytotoxicity against HNSCC. It is derived 
from HSV-1 strain F. It has multiple mutations including deletions at both loci of the 
ICP34.5 gene and insertion of a LacZ reporter gene into the ICP 6 gene (Mineta et al,
1995). The ICP6 gene encodes the large subunit of HSV ribonucleotide reductase, 
and loss of its expression decreases the ability of 0207 virus to proliferate in 
nondividing cells. The specificity for tumour cell lysis is increased. The multiple 
mutations of 0207 are thought to minimise the chance of reversion to wild-type virus. 
In vitro and in vivo studies showed 0207 to infect and cause efficient lysis of 
HNSCC (Carew et al, 1999; Chahlavi et al, 1999). Carew et al, 1999, used human 
s e e  cell lines and trypan blue to assess cell viability. Cell death progressively 
increased with increasing MOIs. Animal studies involved direct inti’atumoural 
injections into murine flank tumours as well as selective inti'a-arterial perfusion of 
oral cavity tumours. All experiments showed inliibition of tumour growth.
NV1020 is another multi-mutated HSV-1 oncolytic vims, which has shown 
cytotoxicity to HNSCC in vitro and in vivo. It has deletions of one copy of ICP 34.5 
and the virulence-associated virion gene, UL 56. It also has a deletion in the 
thymidine kinase locus. As NV1020 was originally designed as a potential HSV 
vaccine, a fragment of HSV-2 DNA is inserted into the UL/S junction. This junction 
also contains an exogenous copy of the HSV-1 thymidine kinase gene under control 
of the strong ICP 4 promoter, in addition to a duplication of the UL5/6 sequences. In
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vitro studies showed NV1020 to be highly cytotoxic to five human HNSCC lines 
(Wong et al, 2001). Tumour regression was seen following injections into flank 
tumours in a murine model. Biopsies fiom tumours identified areas of necrosis 24 
houi's post-injection. There have been no clinical trials involving G207 or NV1020 
and head and neck cancer patients.
Using HSV1716 we found all 3 cell lines were permissive to infection with variable 
sensitivity and variable cytotoxic effects. It therefore seems likely that this vims may 
be efficacious by intratumoural injection, though in vivo experiments are required to 
validate this. The use of oncolytic vimses in isolation may not necessarily produce an 
efficacious effect comparable to, or better than currently available therapies. 
Combining agents with different mechanisms of cytotoxicity is an attractive approach 
and gives a number of potential advantages. It gives potential for using lower doses, 
maximising the therapeutic effect and minimising side effects. Combining therapies 
also gives potential for enhanced effects, tlnough different mechanisms of 
cytotoxicity. These interactions can be antagonistic, additive or synergistic.
This approach has already been reported by Toyoizmni et al, 1999. They combined 
HSV1716 with cytotoxic agents but in a different tumour type. In-vitro studies in 
non-small cell lung cancer showed, with isobologram analysis, synergistic effects 
between HSV1716 and mitomycin C (MMC). The synergistic dose of MMC neither 
augmented nor inhibited viral replication in vitro. The mechanisms of action involved 
in this synergy are unclear. The combination of MMC with HSV1716 yielded an 
additive effect in a murine xenograft model. It was reasoned that the difference 
between the in vitro and in vivo results, was related to the duration of MMC cell
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contact. Additive effects were found in vitro combining HSV17Î6 with cw-platinum 
II, methotrexate or doxorubicin.
In vivo cytotoxicity studies involving oncolytic HSV-1 mutant G207 combined with 
cisplatin showed additive tumouricidal effects in one of two established human 
HNSCC murine flank tumours (Chahlavi et al, 1999). No increased toxicity was 
noticed. There was no enhanced kill in the other tumour model, and it was noted that 
the cell type involved was less sensitive to cisplatin. The G207 and cisplatin appeared 
to be acting independently. G207 and HSV1716 undergo extensive DNA replication 
and transcription as they replicate in and kill tumour cells. These processes could be 
blocked by cisplatin, so it was necessary to determine whether cisplatin was toxic to 
the vims. Cisplatin blocks DNA replication by producing damaging intrastrand DNA 
cross-links (Pinto et al, 1985; Heiger-Bemays WJ et al, 1990). Cisplatin was not 
found to be toxic to G207, corresponding with our results for HSV1716. We did not 
use any cell lines which are poorly sensitive to cisplatin. This may have given us 
infoimation regarding any dependency between HSV1716 and cisplatin.
Heise et al, 1997, investigated the cytotoxic effects of the mutated adenovims 
ONYX-015, combined with cisplatin and 5-fluoroui-acil (5FU) in a HNSCC tumour 
xenogi'aft. Cisplatin and 5FU were found to be more effective than chemotherapy or 
virus treatment alone. The median suivival was significantly increased with 
combination therapy, compared with chemotherapy alone.
Kluui et al, 2000, combined ONYX-015 with cisplatin and 5-fluorouracil in patients 
with recun'ent head and neck cancer. In this study, enhanced efficacy was found with 
the combination of agents compared to responses reported in the literature with
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cisplatin and 5-fluorouracil alone. Replicating herpes simplex viruses may have 
potential advantages over adenoviruses due to their more potent replication capacity 
producing a greater cytopathic effect. We therefore wanted to evaluate the effect of 
combining HSV1716 with cisplatin in the 3 head and neck cell lines studied. These 3 
cell lines have already been studied for cisplatin sensitivity as reported by Welters et 
al, 1997. In our* study we were able to produce similar results demonstrating that cell 
line 22A was the most sensitive and 14C the least sensitive. When we evaluated the 
effect of combining HSV1716 with cisplatin we found additive cytotoxicity using 
isobologram analysis. Further in vivo studies are warranted to evaluate the effects of 
these combined agents in nude mouse HNSCC xenogiafts. If this is observed then the 
potential exists for utilising these agents in patients with locally advanced or 
locoregional recurrent head and neck cancer in a phase I tiial.
We have shown that HNSCC is a potential target for the selectively replicating herpes 
simplex virus HSV1716. More importantly we have shown that combining this agent 
with cisplatin has additive cytotoxicity in this cell type. This combination of agents 
may therefore be potentially useful as a novel therapy in patients with locally 
advanced or locoregional recurrent head and neck cancer. Since HSV1716 has 
already been used in clinical trials in glioma and melanoma with no serious toxicity 
and with evidence of efficacy, our in vitro experiments in HNSCC enabled us to 
conduct a phase I trial with this agent in HNSCC by inhatumoral injection. We aimed 
to determine if HSV1716 could be injected easily, comfortably and safely in patients 
with oral squamous cell carcinoma
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5.3 PHASE I STUDY OF PREOPERATIVE INTRATUMOURAL 
INJECTION OF HSV1716 IN ORAL SQUAMOUS CELL CARCINOMA
HSV1716 lias not been previously investigated in HNSCC. The primary objective of 
this Phase I study was to deteimine the safety of a single intratumoural injection of 
HSV1716 in patients with oral squamous cell carcinoma. The results obtained 
showed the therapy to be completely safe with no toxicity. The maximum dose 
injected was 5x10^ pfu. The procedure was technically uncomplicated and well 
tolerated under local anaesthetic. The lack of toxicity is encoui’aging and suggests 
higher doses could be used in future trials.
HSV1716 injection did not cause any clinically apparent tissue reaction. There were 
no signs of increased inflammation or ulceration of the injected tumour or buccal 
mucosa. H&E slides of sections of tissue at the tumour injection site did not identify 
any unexpected inflammation or necrosis. H&E slides of sections of tissue of injected 
noimal buccal mucosa revealed lymphocyte infiltiations and no necrosis. HSV DNA 
was detected by PCR in injected normal mucosa in 3 patients up to 72 hours post­
injection. There was no infectious vims recovered from any normal mucosa samples 
and no positivity in immunohistochemistry or in situ hybridisation analysis. Overall 
HSV1716 injection of normal mucosa appears to have consistently caused an 
inflammatory reaction, but no necrosis and we have found no evidence of viral 
replication. HSV1716 inoculation of normal tissue has not been investigated before. 
Nemunaitis et al, 2000, reported results following the inoculation of normal mucosa 
with the selectively replicating adenovims ONYX-015. They identified the presence 
and/or replication of ONYX-015 in tumour tissue on days 5-14 post injection, but not
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in adjacent normal mucosa. However caution is needed in interpreting these results as 
their injection protocol involved only direct intratumoural injections, up to the 
periphery of the tumours. There were no separate injections of normal mucosa, 
distant from the tumour, and no separate analyses of the nomial mucosa.
The use of intratumoural injection of oncolytic vimses in HNSCC has already been 
reported using ONYX-015 (Ganly et al, 2000; Nemunaitis et al, 2000; Kliuri et al,
2000). Replicating herpes simplex viruses may have potential advantages over 
adenoviruses due to their inherent greater replication capacity producing a more 
potent cytopathic effect. In the ONYX-015 studies far higher doses of virus were 
used, up to 10*^  pfu , with no significant toxicity reported. A different injection 
protocol was used in these studies. At each injection the ONYX-015 was distributed 
evenly along at least 8 needle tracts radiating from a central penetration site. Also the 
virus was diluted to a volume estimated to be 30% of the tumour volume. Our 
approach with HSV1716 was to concentrate the vims in a small defined area of the 
tumour, and the vims was injected in a concentrated small volume. Biopsies were 
then taken at the time of tumour resection from the vims injection site and from distal 
sites, far away from the injection site. HSV DNA was detected by PCR in only one 
biopsy taken from a site distant from the injection site. There was no infectious 
HSV1716 recovered from the specimens and no positive identification of HSV in the 
iimnunoliistochemistry or in situ hybridisation analyses. Overall the lack of evidence 
of HSV1716 in the tumours at resection, and the lack of evidence of antitumour effect 
is disappointing. Using a higher dose of HSV1716 and distributing the virus evenly 
thi'oughout the tumom's in a larger volume may be more beneficial. Ganly et al, 2000,
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noted increased pain associated with liigher injection volumes, but tliis could be aided 
by the use of local anaesthetic injections in addition to a spray. It is possible that there 
is significant leakage of vims from the needle penetration site, and using a higher 
dose of vims with a wider distribution would aid this. Further, it has been shown in 
an animal study in nude mice that the distribution of an oncolytic virus is more 
widespread with a multi-injection protocol. (Heise et al, 2000). Two clinical trials 
with ONYX-015 have used a multi-injection protocol in HNSCC. Both studies 
demonstrated selective intratumoui'al replication and necrosis in patients.
Biological activity in HNSCC following HSV1716 injection in humans is lacking. 
HSV DNA was only identified at the injection sites in 2 patients, 1 at 24 horns and 1 
at 72 hours post-injection. There was only one potential sign of intratumoui'al 
HSV1716 replication, from HSV DNA identified in a tumour biopsy distant from the 
injection site. No conclusions can be drawn from this single result. Possibilities of a 
contaminated sample and the detection of wild type vims have to be considered. 
Further studies need to investigate possible immune factors which could affect viral 
spread in HNSCC in humans. Evidence suggests the presence of humoral immunity is 
not a cmcial factor. Two out of 20 patients injected with HSV1716 were seronegative 
for HSV antibodies prior to injection. Both seroconverted within 5 weeks of their 
injection, indicating an immune response. The seropositive patients did not have any 
changes in their HSV neutralising antibodies post injection. Ganly et al, 2000, noted 
all but one of the 22 patients treated to develop increased antibody levels, following a 
single injection protocol. The clinical studies with ONYX-015 have found no 
coiTelation between the adenovims neutralising antibody titres before and after
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treatment, and the measniable tumour response. Patients who received a multi­
injection protocol were noted to have tumour responses despite as many as 5 cycles 
of prior viral therapy and very high antibody titres (Klimi et al, 2000; Nemunaitis et 
al, 2000). Following HSV1716 injection in oral SCC, the patient who had HSV DNA 
detected by PCR from a distal biopsy site was seropositive. This data conesponds to 
results from a clinical study involving the intratumoural injection of HSV1716 in 
patients with glioblastoma multifomie (Papanastassiou et al, 2002). HSV DNA was 
identified by PCR analysis of biopsies from distal tumour sites in 4 seropositive 
patients. Such a result caimot be extrapolated too far as the brain has a distinct 
immune system. However further evidence that HSV antibodies do not stop 
HSV1716 from replicating and killing tmnom- cells was noted in a clinical trial 
injecting HSV1716 into cutaneous melanoma nodules. 2 Injections into the same 
melanoma nodule in a seropositive patient resulted in tumour flattening (Mackie et al,
2001). This data supports the theory that antibody penetration into solid tumours is 
markedly reduced (Jain et al, 1994). Seropositivity and rising antibody levels seem to 
have no effect on repeat intratumoural administration, and would only become 
important in repeat systemic viral injection.
Further studies need to look at the roles of cell mediated immunity and local 
immmiity following the intratumoural injection of HSV1716 in HNSCC. Cell 
mediated immimity (CMI) is mediated by cytotoxic T lymphocytes. It involves the 
activation of macrophages, the production of antigen-specific cytotoxic T- 
lymphocytes and the release of cytokines in response to an antigen. CMI is stimulated 
by HSV antigens produced in the host cell and presented along with major
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histocompatibility complexes on the cell surface. This can cause early elimination of 
virus. McKie et al, 1998, studied the immune response induced following direct 
intracerebral inoculation of HSVI716 in immune naive mice. They identified a time- 
dependent immune response, consisting of a mild infiltration by macrophages and T- 
lymphocytes. This occurred mainly at the site of inoculation with a maximal response 
at approximately 7 days post-inoculation. The central nervous system is however an 
immimologically privileged site. It is able to exclude immune components of the 
immune system by the blood-brain barrier. Neural astrocytes and microglial cells play 
a major role in the generation of the intracerebral immune response (Fontana et al, 
1987; Hart et al, 1995). These are important differences when considering the fate of 
HSV1716 injection into solid tumours such as HNSCC.
Investigations are needed into the interactions between HSV1716 replication in 
HNSCC cells and the immune system. A quantitative and qualitative analysis of 
helper T lymphocyte (CD4), cytotoxic T lymphocyte (CD8) and macrophage (CD68) 
infiltration following viral injection is indicated. A qualitative analysis is required as 
it is documented that T lymphocyte function is impaired in HNSCC (Pandit et al, 
2000; Ballet et al, 1997). hicoiporated into this should be a study of the role of 
cytokines and their impact on HSV1716 replication. Tumours secreting the cytokine 
interferon may neutralise viral spread. It is documented that T-cell derived gamma 
interferon (IFN-y) can directly inhibit in vivo the replication of HSV-1, and may have 
a synergistic role with IFN-a and IFN-(3 (Sainz et al, 2002). Head and neck cancer 
cells secrete cytokines and it has been shown that cytokine levels and activities are 
increased by cisplatin in patients with HNSCC (Okamoto et al, 2000). This increase
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in antitumour immunity could therefore have a negative effect on HSV1716 
replication when contemplating combining HSV1716 and chemotherapy agents in 
humans. This needs further investigation.
5.4 FURTHER DEVLOPMENTS
In summary we have shown in vitro that the selectively replication competent 
oncolytic virus, HSV1716, is able to replicate in and kill HNSCC cell lines. 
Cytotoxicity studies have shown, following isobologram analysis, that there is 
additive enhanced cell kill when HSV1716 is combined with the conventional 
chemotherapy agent cisplatin. We do not know the relationship between the 
mechanisms of action of these 2 agents and this needs further investigation. They 
could act completely independently of each other. We have shown that cisplatin is not 
toxic to HSV1716. Further in vivo studies are warranted to evaluate the effects of 
these combined agents in nude mouse HNSCC xenografts. If this is observed then the 
potential exists for utilising these agents in patients with locally advanced or 
locoregional recui'rent head and neck cancer in a phase I trial. Potentially higher 
doses of HSV1716 could be used, with an aim of injecting liigher volumes and 
distributing the virus evenly tliroughout the tumoui-.
Following completion of a Phase I toxicity study we have shown that HSV1716 can 
be injected into patients with oral SCC readily, comfortably and safely. There was no 
toxicity in any of the 20 em'olled patients. Current therapies for recurrent head and 
neck cancer, such as tumour debulking, further irradiation and chemotherapy have all 
produced poor responses of limited duration, and significant morbidity. HSV1716 has 
the potential to complement and improve conventional therapies.
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Overall these findings are ideal attributes for a replication selective oncolytic virus. 
However we found little evidence of biological activity in the tumour specimens 
analysed in the clinical tiial. ONYX-015 also demonstrated less cell killing potential 
in a clinical setting than was expected from preclinical studies (Bischoff et al, 1996). 
It is known that although viruses rapidly spread in cell cultine monolayers, viral 
spread within a solid tumour mass is often limited (Heise et al, 1999), The tumoui' 
matrix may present potential physical limitations to viral spread, including fibrosis, 
intermixed normal cells and necrotic regions. Less than 20% of the heterogeneous 
cells that make up oral tumours are in the S-phase of replication. This is reported to 
be an important factor limiting the replication of oncolytic HSV-1 (Shillitoe et al, 
2005). It will be important to fuither evaluate approaches that improve viral spread 
within a tumoui', as it is one of the most important factors for antitumour efficacy 
following intratumoural injection. Experiments could be performed to confirm the 
PCNA expression in tumour cells from biopsies, and to quantify the percentage of 
cells in different stages of the cell cycle. If a small percentage of cells are found to be 
in the S-phase of replication, this will have a limiting factor on the replicative 
capability of HSV1716.
Better understanding of the binding and subsequent replication of the virus in the 
tumour cells could identify mechanisms to increase the efficacy in vivo. A number of 
studies have reported that primary cancer cells from humans express only low levels 
of the primary adenovirus receptor, and are therefore poorly infected by adenoviruses 
(Dmitriev et al, 1998; Miller et al, 1998; Li et al, 1999). An in vivo study with 
replicating adenovirus found that the absence of the primary cellular receptor on
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tumour cells restricts the oncolytic potency of the vims (Douglas et al, 2001). This 
suggests the efficacy of replicating adenovimses could be improved by altering the 
virus to allow infection via a different pathway. Shinouia et al, 1999, reported the 
potency of a replicating adenovims in glioma cell lines, in vitro and in vivo, could be 
improved by the addition of 20 lysine residues to the COOH terminal o f  the fibre 
protein. This allowed the vims to bind to cellular heparin sulphate receptors.
The binding of HSV to cells and subsequent replication is different to adenovirus. 
Cell surface carbohydrate molecules frequently serve as initial receptors for viruses. 
The initial virus-cell contact is followed by multiple interactions between numerous 
copies of the viral attachment proteins and receptor molecules. The heparin sulphate 
proteoglycan is the molecule first identified to serve as an initial receptor for HSV-1 
(WuDunn and Spear, 1989). Heparin sulphate proteoglycans are found on the surface 
of cells susceptible to HSV infection (Lycke et al, 1991; Gerber et al, 1995). Removal 
of heparin from the cell surface has been shown to render the cells at least partially 
resistant to HSV infection by reducing vims attachment to the cell sui'face (Shieh at 
al, 1992). Syndecan is a family of four transmembrane heparin sulphate 
proteoglycans. Syndecan-1 expression has been shown to be reduced during 
malignant transformation of various epithelia. This loss correlates with the 
histological differentiation grade of squamous cell carcinoma. In HNSCC, positive 
syndecan-1 expression correlates with a better clinical prognosis (Inki and Jalkanen,
1996). This indicates replication of HSV will be poorer in aggressive HNSCC 
tumoui's. Investigations are therefore needed into the binding of HSV1716 with 
HNSCC cells, and the subsequent replication in the solid tumour matrix.
157
For HSV1716 to have a therapeutic role in HNSCC we need to investigate the 
immune response to HSV1716 inoculation, and its impact on viral replication and 
spread. Neutralising antibodies do not appear to block replication following 
intratumoural injection (Nemunaitis et al, 2000; Ganly et al, 2000). However IgM and 
complement have been shown to impede intravenous efficacy of oncolytic HSV-1 
(Ikeda et al, 1999; Ikeda et al, 2000). Intravenous delivery of HSV-1 oncolytic 
viruses, NV1020 and G207, was found to be less effective than regional hepatic 
arterial delivery in treating hepatic nodules in mice previously exposed to the virus. 
Viral inactivation by the host appears to significantly limit systemic herpes oncolytic 
efficacy and the role of HSV1716 as a systemic therapy remains a very distant 
prospect. Tumoui' targeting with cell-specific delivery of virus will improve the 
systemic treatment of distant metastatic disease. There is some inherent targeting as 
the capillaries present in tumours are leakier than in normal tissue and this allows 
viral particles to selectively concentrate in the tumour. Active tumoui' targeting has 
been shown in vivo by attaching ligands, such as basic fibroblast growth factor or 
epidermal growth factor to an adenovirus capsid (Gu et al„ 1999; Cuiiel, 1999). 
Jakubczak et al, 2001, demonstrated increased targeting of adenovirus type 5 by 
modifying the protein coat, allowing increased infectibility in coxsackievirus- 
adenovirus receptor (CAR) deficient tumours.
Cell-mediated immunity and local immunity will limit efficacy of oncolytic viruses 
and could be a significant reason for the lack of evidence of biological activity in our 
study. It is notable however that the immune response is not all inliibitory. Viral 
replication within tumours can lead to the induction of cytokines with antitumoural
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properties. This concept can be harnessed to produce a therapeutic effect. In vivo 
studies have demonstrated inhibition of tumoui' growth by stimulating localised 
inflammatory or immune responses by transducing tumour cells with cytokines and 
gi'owth factor genes such as inteleukin IL-1 (Douvedani et al, 1992), IL-2 (Fearon et 
al, 1990), IL-4 (Golumbek et al 1991; Tepper et al, 1994), interferon (IFN-y) 
(Porgador et al, 1992; Restifo et al, 1993) and tumour necrosis factor (Blankenstein et 
al, 1991; Asher et al, 1991). IL-12 is a cytokine secreted by antigen presenting cells 
such as dendritic cells, monocytes, macrophages and B-lymphocytes. It is an 
important mediator in cell mediated immunity by promoting helper T-lymphocyte 
development. It has been shown to increase antitumour effects in a murine HNSCC 
model (Myers et al, 1998). Wong et al, 2004, studied the effects of intravenous herpes 
oncolytic viruses NV1023 and NV1042 in a pulmonary metastatic HNSCC mmine 
model. These viruses are identical except that the murine IL-12 gene has been 
inserted into the deleted joint sequence. Both have equivalent oncolytic efficacy in 
lysing SCC in vitro, but NV1042 administered intratumourally exhibited significantly 
greater therapeutic effects in mice bearing SCC tumours. IL-12 expression by 
NV1042 generated an antitumoural immune response that enhanced oncolytic 
efficacy (Wong et al. 2001). Animals with disseminated SCC that were treated with 
systemic NV1042 survived significantly longer compared with NV1023 tieated 
animals. It is notable that during animal CD4 and CD8 depletion studies the suivival 
advantage of NV1042 was almost abolished. This indicates IL-12 benefit was 
mediated through T-lymphocyte activity. Understanding the limiting impact of the 
immune response on viral replication, and the potential enhanced antitumoural
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effects, will be cmcial in the future investigation of the potential therapeutic role of 
HSV1716 intratumoui’al injection in locally advanced or locoregional recui’rent head 
and neck cancer.
Another approach to try and increase the antitumour activity of HSV1716 in HNSCC 
involves altering the vims to express cytotoxicity enhancing proteins. Nakaniori et al, 
2003, increased the fusogenic capability of HSV-1 by screening for a syncitial HSV 
after random mutagenesis and insertion of a hyperfusogenic glycoprotein from 
gibbon ape leukaemia virus into the viral genome. The modified virus kills tumour 
cells efficiently tlnough both replication and cell membrane fusion. This dramatically 
increased the cytotoxicity of the vims following injection into the abdominal cavity 
of mice bearing human ovarian cancer. Fu et al, 2002, constiucted an oncolytic virus 
with a syncitial phenotype, which was derived from the oncolytic HSV-1 viius G207. 
There was a dramatic antitumour activity in vivo against pulmonary metastatic breast 
cancer, and notably greater than G207. Increasing the cell membrane fusion of 
HSV1716 in HNSCC could be explored. Any alterations to the virus, for example 
changes to its phenotypic characteristics, must not be detrimental to its replicative 
viability and its fundamental clinical safety.
Combining oncolytic viruses with other ti’eatments has the potential of achieving 
gi'eater antitumour effects than either of these therapies alone. We have shown 
enhanced cytotoxicity in vitro when HSV1716 is combined with cisplatin in HNSCC. 
Further studies could be done to investigate the interaction between HSV1716 and 
radiotherapy, another mode of treatment in HNSCC. A similar in vitro MTS assay 
methodology could be adopted. Enhanced cytotoxicity of glioma cells was found
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when HSV1716 was combined with radiotherapy (Harrow SJ, personal 
communication). ONYX-015 when combined with radiotherapy enhanced tumour 
control greater than that of either monotherapy in a human colorectal carcinoma 
murine model (Rogulski et al, 2000). Enhanced therapeutic effects v/ere also 
observed when treatment with the HSV-1 mutant NV1020 was combined with 
ionising radiation both in human U-87 malignant glioma and Hep3B hepatoma 
mmine models (Advani et al, 1998; Bradley et al, 1999; Chung et al, 2002) Overall 
radiation does not appear to impair, and potentially enhances viral replication of 
HSV1716, ONYX-015 or NV1020. This indicates that, imlike human genomes, viral 
genomes suffer relatively little damage by ionising radiation. Multimodal cancer 
management with therapies which have different safety profiles has the advantage of 
potential enlianced efficacy without increased toxicity. It may be possible to lower 
treatment doses, thereby decreasing possible toxicity, and still achieve greater 
efficacy than with single therapies. Also there should be no overlapping resistance 
between HSV1716 and cisplatin or radiotherapy.
In conclusion, the preclinical studies involving HSV 1716 in HNSCC cells alone and 
in combination with cisplatin are encouraging. There is in vitro evidence of enlianced 
cytotoxicity when HSV1716 is combined with the conventional chemotherapy agent 
cisplatin. Intiatumomal injection of HSV1716 into human oral squamous cell 
carcinoma can be performed readily, comfortably and safely. As has been seen with 
other oncolytic viruses, the effective application is not as straightforward as 
laboratory studies might have indicated. The principle problem areas involve 
optimising the delivery and distribution of HSV1716 into a dense heterogeneous SCC
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tumour cell matrix. Increasing our knowledge of the interactions between HSV1716, 
the HNSCC tumour cell and the immune system will help to optimise antitumour 
efficacy. This will maximise its ability to disseminate throughout a tumour mass and 
endui'e efficacy, despite encountering the immune response. Overcoming these 
hurdles will enable HSV1716 to be used as a multimodal head and neck cancer 
treatment, with the golden aim of destroying tumours and improving the survival of 
cancer patients.
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